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A B S T R A C T
Background
Depressive disorders are common in children and adolescents and, if left untreated, are likely to recur in adulthood. Depression is
highly debilitating, affecting psychosocial, family and academic functioning.
Objectives
To evaluate the effectiveness of psychological therapies and antidepressant medication, alone and in combination, for the treatment of
depressive disorder in children and adolescents. We have examined clinical outcomes including remission, clinician and self reported
depression measures, and suicide-related outcomes.
Search methods
We searched the Cochrane Depression, Anxiety and Neurosis Review Group’s Specialised Register (CCDANCTR) to 11 November
2011. This register contains reports of relevant randomised controlled trials (RCTs) from the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE (1950 to date), EMBASE (1974 to date), and PsycINFO (1967 to date).
Selection criteria
RCTs were eligible for inclusion if they compared i) any psychological therapy with any antidepressant medication, or ii) a combination
of psychological therapy and antidepressant medication with a psychological therapy alone, or an antidepressant medication alone, or
iii) a combination of psychological therapy and antidepressant medication with a placebo or ’treatment as usual’, or (iv) a combination
of psychological therapy and antidepressant medication with a psychological therapy or antidepressant medication plus a placebo.
We included studies if they involved participants aged between 6 and 18 years, diagnosed by a clinician as having Major Depressive
Disorder (MDD) based on Diagnostic and Statistical Manual (DSM) or International Classification of Diseases (ICD) criteria.
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Data collection and analysis
Two review authors independently selected studies, extracted data and assessed the quality of the studies. We applied a random-effects
meta-analysis, using the odds ratio (OR) to describe dichotomous outcomes, mean difference (MD) to describe continuous outcomes
when the same measures were used, and standard mean difference (SMD) when outcomes were measured on different scales.
Main results
We included ten studies, involving 1235 participants in this review. Studies recruited participants with different severities of disorder
and with a variety of comorbid disorders, including anxiety and substance use disorder, therefore limiting the comparability of the
results. Regarding the risk of bias in studies, half the studies had adequate allocation concealment (there was insufficient information to
determine allocation concealment in the remainder), outcome assessors were blind to the participants’ intervention in six studies, and
in general, studies reported on incomplete data analysis methods, mainly using intention-to-treat (ITT) analyses. For the majority of
outcomes there were no statistically significant differences between the interventions compared. There was limited evidence (based on
two studies involving 220 participants) that antidepressant medication was more effective than psychotherapy on measures of clinician
defined remission immediately post-intervention (odds ratio (OR) 0.52, 95% confidence interval (CI) 0.27 to 0.98), with 67.8% of
participants in the medication group and 53.7% in the psychotherapy group rated as being in remission. There was limited evidence
(based on three studies involving 378 participants) that combination therapy was more effective than antidepressant medication alone
in achieving higher remission from a depressive episode immediately post-intervention (OR 1.56, 95% CI 0.98 to 2.47), with 65.9%
of participants treated with combination therapy and 57.8% of participants treated with medication, rated as being in remission. There
was no evidence to suggest that combination therapy was more effective than psychological therapy alone, based on clinician rated
remission immediately post-intervention (OR 1.82, 95% CI 0.38 to 8.68).
Suicide-related Serious Adverse Events (SAEs) were reported in various ways across studies and could not be combined in meta-analyses.
However suicidal ideation specifically was generally measured and reported using standardised assessment tools suitable for meta-
analysis. In one study involving 188 participants, rates of suicidal ideation were significantly higher in the antidepressant medication
group (18.6%) compared with the psychological therapy group (5.4%) (OR 0.26, 95% CI 0.09 to 0.72) and this effect appeared to
remain at six to nine months (OR 1.27, 95% CI 0.68 to 2.36), with 13.6% of participants in the medication group and 3.9% of
participants in the psychological therapy group reporting suicidal ideation. It was unclear what the effect of combination therapy was
compared with either antidepressant medication alone or psychological therapy alone on rates of suicidal ideation. The impact of any
of the assigned treatment packages on drop out was also mostly unclear across the various comparisons in the review.
Limited data and conflicting results based on other outcome measures make it difficult to draw conclusions regarding the effectiveness
of any specific intervention based on these outcomes.
Authors’ conclusions
There is very limited evidence upon which to base conclusions about the relative effectiveness of psychological interventions, antidepres-
sant medication and a combination of these interventions. On the basis of the available evidence, the effectiveness of these interventions
for treating depressive disorders in children and adolescents cannot be established. Further appropriately powered RCTs are required.
P L A I N L A N G U A G E S U M M A R Y
Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Depressive disorders are common in children and adolescents, with suggested overall prevalence rates for adolescents (13 to 18 years)
being 5.7% and for children (under 13 years) 2.8%. Common symptoms of depression in children and adolescents include low mood,
a loss of interest in once enjoyed activities, difficulties with concentration and motivation, changes in appetite and sleep, irritability,
physical symptoms such as headaches or stomach aches and in some cases thoughts of suicide. If left untreated, depressive disorders in
the younger years are likely to continue into adulthood, and can be increasingly difficult to treat as time goes on. Both psychological
therapies and antidepressant medication can be used to treat depression in children and adolescents. Psychological therapies, sometimes
called ’talking therapies’, involve working with a qualified therapist to treat the depression. Psychological therapies in common use are
cognitive behavioural therapy (CBT), interpersonal psychotherapy (IPT) and psychodynamic therapy. There are many different types of
antidepressant medication, all of which have been developed specifically to work on chemicals in the brain that are believed to be linked
to depression. Research has been undertaken on psychological therapies and antidepressant medication, alone and in combination, to
asses the effects of these interventions on depression in children and adolescents.
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In order to asses whether either intervention or a combination of both is most effective, we included studies that compared: (1)
any psychological therapy with any antidepressant medication; (2) any combination of these therapies (a psychological therapy plus
antidepressant medication) with either psychotherapy alone or antidepressant medication alone; (3) any combination of these therapies
(a psychological therapy plus antidepressant medication) with a placebo or ’treatment as usual’; (4) any combination of these therapies
(a psychological therapy plus antidepressant medication) with either therapy plus a placebo.
We included 10 randomised controlled trials (RCTs) involving 1235 participants in this review. These trials made a variety of different
comparisons and only a small number of trials contributed information about each of the comparisons made in the review. Although
most analyses included more than one trial, the results of these trials sometimes differed considerably or were even contradictory. In
terms of adverse effects of treatment, in one trial, rates of suicidal thoughts were higher in those taking antidepressant medication,
compared with those delivered psychological therapy. Overall, it was not possible to draw robust conclusions from the meta-analyses,
nor to establish which intervention strategy was most effective.
In summary, on the basis of the available evidence, we do not know whether psychological therapy, antidepressant medication or a
combination of the two is most effective to treat depressive disorders in children and adolescents.
B A C K G R O U N D
Description of the condition
As recently as the 1970s, it was widely believed that depressive
disorder in young people was very rare (Baker 2006). However,
it is now well established that depression is a common disorder
in this population. A 2006 meta-analysis suggested overall preva-
lence rates for adolescents (13 to 18 years) to be 5.7% and for
children (under 13 years) to be 2.8% (Costello 2006), born be-
tween 1965 and 1996. Lifetime estimates range between 15% and
20% (Birmaher 1996). Depressive disorder is debilitating and af-
fects psychosocial, family and academic functioning (Lewinsohn
1998). Major depressive disorder (MDD) is one of the leading
causes of disability, morbidity and mortality (WHO 2008) and
is a major risk factor for suicide. Children and adolescents with
MDD are seven times more likely to complete suicide than those
without (Gould 1998). Furthermore, approximately 70% of ado-
lescents with MDD will relapse within five years, and adolescents
who experience depression are four times more likely to develop a
depressive disorder in adulthood compared to adolescents who do
not suffer from depression (Richmond 2005). Early onset depres-
sion is also associated with treatment resistant depression later in
life (Hatcher-Kay 2003).
Diagnostic criteria for depressive disorders are essentially the same
for adults and children, although specific signs and symptomsmay
differ in children and adolescents. In adults, a diagnosis is reached
through a consultationbetween the patient and the clinician,while
for children and adolescents a diagnosis is often made using infor-
mation from multiple sources including parents, teachers, coun-
sellors, healthcare professionals, as well as the child or young per-
son themselves (Emslie 2005). Compared with adults, depressed
children and adolescents may exhibit higher levels of anxiety and
irritability, ‘temper tantrums’, behavioural problems, social with-
drawal, phobias, and exaggerated somatic symptoms. Symptoms
of melancholia, psychosis, suicide attempts, lethality of suicide at-
tempt, and impairment of functioning appear to increase with age
(Birmaher 1996), and it has been established that treatments are
not uniformly effective across age groups (Emslie 2005).
Description of the intervention
A number of psychological therapies have been trialed as a treat-
ment forMDDin children and adolescents. Cognitive behavioural
therapy (CBT) has been the most widely studied, and trials have
also been conducted into the effectiveness of interpersonal therapy
(IPT), behaviour therapy, and problem-solving therapy. A recent
systematic review (Watanabe 2007) indicated that overall, psy-
chotherapy was more effective than control comparisons imme-
diately post-intervention, although this benefit was no longer ev-
ident at six months and 12 months follow-up. Subgroup analysis
suggested that psychotherapymight bemore effective than control
for adolescents (13 to 19 years) but not for younger children (six
to 12 years), and might be more beneficial than wait-list control,
but no more effective than attention/placebo.
The majority of guidelines on the treatment of depressive disor-
ders in young people recommend the judicious use of medica-
tion, specifically selective serotonin reuptake inhibitors (SSRIs),
in the context of careful monitoring of symptoms and side ef-
fects (AACAP 2007; Cheung 2008a; NICE 2005; Zuckerbrot
2007). The SSRI for which there is themost consistent evidence of
a statistically significant reduction in depressive symptoms com-
pared with placebo is fluoxetine (Hetrick 2007; Richmond 2005;
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Whittington 2004). The Committee on the Safety of Medicines
(CSM) (CSM 2004) and the Food and Drug Administration
(FDA) (FDA 2004) recommend it as the preferred SSRI for use
in young people, and the National Institute for Health and Clin-
ical Excellence (NICE) guidelines state specifically that fluoxe-
tine should be the first antidepressant medication option (NICE
2005).
How the intervention might work
In psychological therapies the aim is to build a relationship with
the client through a structured and purposeful encounter, and
although a range of specific techniques are employed, life issues and
problems can be discussed and addressed. Just as there are many
approaches to psychological therapies, the assumed mechanism of
action for each varies. However, common to most is the aim to
increase awareness, with the implicit or explicit aim of changing
thoughts, behaviours or emotions to improve the mental health
well-being of the client.
Antidepressant medications are postulated to work via their effect
on neurotransmitters. Each type of medication has a slightly dif-
ferent effect on various neurotransmitters. For example, tricyclic
antidepressants (TCAs) prevent the reuptake by nerve cells of the
neurotransmitters norepinephrine (noradrenaline), serotonin (5-
hydroxytryptimine, or 5-HT) and to a lesser extent, dopamine.
SSRIs block the reuptake of serotonin into the presynaptic (brain)
cell, increasing the level of serotonin available to bind to the post-
synaptic receptor. SSRIs also affect the neurotransmitters nore-
pinephrine and dopamine. Newer antidepressants such as sero-
tonin-norepinephrine reuptake inhibitors (SNRIs), work on both
norepinephrine as well as serotonin reuptake processes.
Why it is important to do this review
Given the prevalence and impact of depressive disorders in chil-
dren and adolescents, it is essential that effective interventions are
identified and implemented. A number of randomised controlled
trials (RCTs) are available to guide treatment decisions for adult
depressive disorder, but the evidence-base for the treatment of
child and adolescent depressive disorder is much less established.
Nevertheless, an increasing number of RCTs of psychological in-
terventions and antidepressant medications are being undertaken
in this population, and several Cochrane reviews of treatments for
depressive disorders in children and adolescents are already avail-
able or underway (Hazell 2002; Hetrick 2007; Watanabe 2004).
Findings fromRCTs have suggested that some psychological thera-
pies might be more effective than a variety of control comparators.
Cognitive behavioural therapy (CBT) has been shown to be more
effective than wait-list control (Lewinsohn 1990; Stark 1987), ’no
treatment’ (Weisz 1997) and life-skills tutoring (Rhode 2004).
Trial data also indicate the efficacy of cognitive therapy (CT), be-
havioural therapy (BT), interpersonal therapy (IPT) and problem-
solving therapy when compared to delayed treatment (Ackerson
1998), wait-list control (Kahn 1990; Stark 1987), clinical mon-
itoring only (Mufson 1999) and ’treatment as usual’ (Mufson
2004).
Trials and reviews conducted into the effectiveness of antidepres-
sant medication in this population have been mixed. Tricyclic an-
tidepressants (TCAs) have been reported to be ineffective for de-
pression in children and adolescents (Hazell 2002; Papanikolaou
2006;Weller 2000). Although there is evidence that selective sero-
tonin reuptake inhibitors (SSRIs) might be more effective than
placebo in this population (Papanikolaou 2006), high dropout
rates, inappropriate outcome measurements, and various poten-
tial reporting biases, mean that these findings should be viewed
with great caution (Dubicka 2006; Hetrick 2007; Whittington
2004). In addition, a recent review compared all classes of antide-
pressant medications with placebo (Tsapakis 2008) and meta-re-
gression analyses indicated no evidence to support the hypothesis
that SSRIs were more effective than TCAs. The lack of robust ev-
idence for the effectiveness of medication continues to stimulate
the debate around its use in treating depression in children and
adolescents (Goodyer 2010; Hetrick 2010).
In the context of the FDA ’black box’ warning on SSRIs about the
increased risk of self injurious ideations and behaviour of young
people on SSRIs (FDA 2004), some guidelines recommend ini-
tial intervention using psychological therapies, for depressive dis-
orders of mild to moderate severity (NICE 2005). Medication is
reserved for more severe disorders and the recommendations high-
light that, when used, antidepressant medication should be used
in conjunction with ongoing psychological intervention (NICE
2005). Two major studies have investigated this approach; the
Treatment for Adolescents withDepression Study (TADS) (March
2004) and AdolescentDepression Antidepressant and Psychother-
apy (ADAPT) (Goodyer 2007). In ADAPT, the addition of CBT
to fluoxetine plus standard care did not appear to improve out-
comes compared to fluoxetine plus standard care Goodyer 2007.
In TADS, fluoxetine alone was superior to CBT alone, and the
combination of fluoxetine and CBT was statistically significantly
better than either alone in the short-term (March 2004). A re-
cent meta-analysis of trials in adult populations found no differ-
ence in efficacy between psychological therapies and antidepres-
sant medication (Bortolotti 2008). Data from the adult literature
also suggest that combination therapy is superior to antidepressant
medication alone (Pampallona 2004) and psychotherapy alone (de
Maat 2007).
The recommendations for treatment of depressive disorders in
children and adolescents exist in the context of relatively little
high quality research, and there have been calls for large, well con-
ducted studies to be undertaken (Hetrick 2007; NICE 2005). A
Cochrane review is timely in providing a review of evidence to
date, examining the potential benefits and harms of psycholog-
ical therapies, antidepressant medication and their combination
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for child and adolescent depressive disorders, and findings could
inform the design and conduct of future trials.
O B J E C T I V E S
1. To determine the effectiveness of psychological therapies
compared with antidepressant medication for treating depressive
disorders in children and adolescents.
2. To determine the effectiveness of a combination of
psychological therapy and antidepressant medication compared
with antidepressant medication alone for treating depressive
disorders in children and adolescents.
3. To determine the effectiveness of a combination of
psychological therapy and antidepressant medication compared
with psychological therapy alone for treating depressive disorders
in children and adolescents.
4. To determine whether the effectiveness of these
interventions differs between children and adolescents.
5. To determine whether the effectiveness of these
interventions differs according to the severity of depressive
disorder.
6. To determine whether there is an increased risk of suicide-
related outcomes in children and adolescents treated with
antidepressant medication alone, compared with psychological
therapy alone, or a combination of treatments.
We added the final objective (6) to the review following the pub-
lication of the protocol. Given the concern that antidepressant
medication may increase suicide-related behaviour in children and
adolescents, we felt it was important to assess the degree of suicide-
related behaviour related to antidepressant medication.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included published and unpublished RCTs, available in any
language, that compared antidepressant medications, psycholog-
ical therapies or their combination. We did not include quasi-
RCTs, or cross-over trials. We included cluster-RCTs and cross-
over trials as a post hoc amendment and we will consider them for
inclusion in the update of the review.
Types of participants
We included children (six to 12 years) and adolescents (13 to 18
years) with a primary diagnosis of depressive disorder, diagnosed
by a clinician using Diagnostic and Statistical Manual (DSM)
or International Classification of Diseases (ICD) categories (APA
2000; WHO 2007). We excluded studies including adults.
While subsyndromal depression can still have a severe impact on
an individuals’ social and educational functioning, because of het-
erogeneity, and because of the lack of data on this group, we did
not include studies of participants with subthreshold depressive
disorder, or studies where depressive disorder was not formally di-
agnosed.
Comorbid conditions are frequently neglected in reviews. We
aimed to include studies where participants had comorbid sec-
ondarymedical or othermental health conditions, including suici-
dal behaviours. It is often difficult to deduce which mental health
condition is deemed primary in clinical practice, and trial authors
did not give information regarding ’primary’ or ’secondary’ diag-
noses as such. Thus, we included trials where all participants were
diagnosed with depressive disorder regardless of the accompany-
ing severity of the comorbid diagnosis.
Types of interventions
We included trials if they compared:
1. any psychological therapy with any antidepressant
medication;
2. a combination of interventions (psychological therapy plus
antidepressant medication) with either psychological therapies or
antidepressant medication alone;
3. a combination of interventions (psychological therapy plus
antidepressant medication) compared with either intervention
(psychological therapy or antidepressants) plus a placebo; and
4. a combination of interventions (psychological therapy plus
antidepressant medication) with a placebo or ’treatment as usual’.
Psychological therapies
• Cognitive behavioural therapy (CBT) uses cognitive
restructuring training and teaching behavioural changes.
• Behavioural therapy (BT) focuses attention on increasing
access to pleasant events and positive reinforcers through the use
of activity scheduling and social skills development.
• Mindfulness training is a common feature of the newer
’third wave’ CBT interventions and involves concentrating on
and attending to, without judgement, whatever is being
experienced at the time of intervention.
• Cognitive therapy (CT) uses cognitive restructuring
training.
• Interpersonal therapy (IPT), whereby the relationship
between mood and relationship problems is explored and the
focus is on improving relationship skills.
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• Problem-solving therapy (PST), focuses on current
problems faced by the participant with evaluation and
subsequent development of solutions to such problems.
• Play therapy (PT) refers to techniques used to engage
participants in activities, such as playing, listening to music, or
outdoor activities, to assist them in coping and dealing with their
problems. It often has psychodynamic underpinnings (Lebo
1958).
• Humanistic therapy (HT) can be described as ’supportive’
therapy, and offers an empathic, non-directive and non-
judgemental approach, based on client-centred principles.
• Psychodynamic therapy (PDT) is where the therapeutic
relationship is used to explore and resolve unconscious conflict
through the use of interpretation and transference.
In order to simplify and reduce the number of categories, we aimed
to group these therapies into four broader groups, based on their
theoretical underpinning. The categories are as follows.
1. CBT (including BT, CT, PST as well as mindfulness
training and other third wave psychotherapies).
2. Integrative therapy (including IPT and cognitive analytic
therapy).
3. Humanistic therapy (including interventions described as
supportive therapy).
4. Psychodynamic therapy (including play therapy).
Antidepressant medications
• Selective serotonin reuptake inhibitors (SSRIs).
• Selective serotonin-norepinephrine reuptake inhibitors
(SNRIs).
• Noradrenergic and specific serotonin antidepressants
(NaSSAs).
• Norepinephrine (noradrenaline) reuptake inhibitors
(NRIs).
• Norepinephrine-dopamine reuptake inhibitors (NDRIs).
• Selective serotonin reuptake enhancers (SSREs).
• Monoamine oxidase inhibitors (MAOIs).
• Tricyclic antidepressants (TCAs).
Given the potentially variable effects of different psychological
therapies and antidepressant medications, we intended to con-
duct subgroup analyses where possible for the (aforementioned)
psychological therapy categories and antidepressant medication
classes listed above.
Combination interventions
We included combination interventions where antidepressant
medication (of any class described above) was combined with psy-
chological therapy (of any type described above).
’Treatment as usual’ and placebo comparison groups
The ’treatment as usual’ condition that was eligible for inclusion
was standard care. We also planned to include wait-list control as
a comparison condition, however there were no instances where
this comparison was used.
Participants in ’treatment as usual’ arms of studies may have been
receiving a psychological therapy, taking antidepressant drugs nat-
uralistically, or both. For this reason, it was our intention to obtain
as much information as possible from the authors regarding the
details of participants’ ’treatment as usual’. Similarly, if details of
the placebo control were not specified, we sought this information.
Where possible, information on ’treatment as usual’ and placebo
control conditionswas described and reported in conjunctionwith
statistical analyses, as we believe variability in ’treatment as usual’
groups may lead to unclear and potentially misleading results.
Follow-up
We searched for studies that examined acute effects of treatment
with at least pre- and post-intervention assessments, and, where
data were available, for longer-term follow-up (maximum of up
to 12 months).
We also included trials where there was an a priori plan for on-
going treatment and follow-up, as well as those where there was
no a priori plan, but in which there was a post-acute, naturalistic
follow-up phase. We endeavoured to obtain as much information
as possible about the treatments that were received by participants
in the studies with naturalistic follow-up. Where planned post-
acute phase treatments (continuation or maintenance phase) took
place, such as formal booster sessions or augmentations, we doc-
umented the treatment.
Types of outcome measures
Primary outcomes
1. Remission from depressive disorder according to a clinical
interview by a mental health professional, using DSM (APA
2000) or ICD (WHO 2007) criteria (dichotomous) for full
remission (eight weeks asymptomatic or free from any significant
mood symptoms respectively). Computerised diagnostic
assessments such as the computerised Diagnostic Interview
Schedule for Children (C-DISC) could also be included.
2. Acceptability of treatment measured by number of
dropouts for any reason.
3. Suicide-related serious adverse events (SAEs). Any suicide-
related SAE, encompassing ideation, attempted suicide including
acts with unknown intent was recorded. However, due to the
diversity of tools in which these data were presented, we did not
combine them in a meta-analysis.
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Secondary outcomes
1. Suicide-related outcomes; we considered these as both a
dichotomous and continuous outcome. For the dichotomous
outcome, we extracted the number of participants with suicidal
ideation, as measured on a standardised, validated reliable scale
such as the Suicidal Ideation Questionnaire-Junior High School
version (SIQ-JR; Reynolds 1987). For the continuous outcome,
we also extracted suicidal ideation, measured on a standardised,
validated measure such as the SIQ-JR.
2. Remission, defined by a cut-off or percentage improvement
on measures such as the Children’s Depression Rating Scale-
Revised (CDRS-R) (Poznanski 1996), Montgomery-Åsberg
Depression Rating Scale (MADRS) (Montgomery 1979), Kiddie
Schedule for Affective Disorders and Schizophrenia for School-
Age Children-Present Episode Version (K-SADS-P) (Brooks
2001), or the Hamilton Depression Rating Scale (HAM-D)
(Hamilton 1960).
3. Improvement in depressive symptoms on clinician rated and
self rated symptom measures (standardised, validated, reliable
scales such as the CDRS-R, MADRS, K-SADS-P, and HAM-D).
4. Level of function measured on clinician rated measures of
general functioning, such as the Global Assessment of
Functioning (GAF; Hilsenroth 2000) and the Children’s Global
Assessment Scale (C-GAS; Shaffer 1983).
5. Number of dropouts due to at least one adverse effect.
Hetrick 2007 provided a list of measures used in the studies that
were included in their SSRI review. It was reasonable to assume
the measures used in the current review would be similar to those
commonly used in SSRI trials. Presented below is a brief overview
of some of these scales.
The CDRS-R is a 17-item clinician interview-based tool to diag-
nose and establish severity of depression in six to 12 year olds. The
first 14 questions are based on response from the child or a parent
or guardian closely related to the child. The final three questions
are rated by the clinician based on non-verbal observations. Ques-
tions are rated on a five or seven-point scale and a final score is
produced by summation of all 17 items (range 17 to 113). This
scale has well documented psychometric properties and has shown
adequate to high reliability and validity across multiple studies
(Brooks 2001).
TheMADRS is a 10-item clinician rated scale assessing depressive
symptoms from the past three or seven days. Each item is scored
on a fixed seven-point scale with a total score ranging from 0 to
60. Psychometric properties for adolescent depression treatment
outcomes have yet to be established (Jain 2007).
The K-SADS-P contains a nine-item depression module com-
pleted by the clinician on the basis of interview. Four of these items
contain two subgroups, each with three questions. A final score
can range from 9 to 56. It covers symptoms from the previous
two weeks and specifically assesses symptoms against theDiagnos-
tic and Statistical Manual for Mental Disorders (DSM; IIIR and
IV) (Brooks 2001). The depression module shows high inter-rater
reliability (Kaufman 1997).
The HAM-D is a clinician rated scale and contains 17 variables
measured on a scale of between zero and two or four (Hamilton
1960). Not all items contain objective criteria for the interviewer
and he or she must use subjective judgement to differentiate re-
sponses as “mild”, “moderate”, or “severe” (Brooks 2001). Items
target depressive symptoms from the previous week. This scale
shows excellent reliability (Myers 2002).
The SIQ-JR is a 15-item self report scale designed to assess the
presence of suicidal ideation in school-aged adolescents.
The GAF is a robust measure of social and general functioning
that exists as the Axis-V of the DSM IV.
The C-GAS is an amended version of the GAF for children and
adolescents under the age of 18 years. It too has a scale of 1 to
100, with 10 levels of functioning, each numeric interval of 10.
If several scales were used to measure the same outcome in a trial,
we chose the measure most commonly used across trials.
We analysed both short- and long-term outcomes, including post-
treatment and follow-up data. We undertook follow-up exami-
nation to show if there were (a) treatments that provide short-
term benefits in terms of response or remission; (b) treatments
that provide short-term benefits that remain over long-term fol-
low-up; and (c) treatments that do not show short-term improve-
ment, however, where the participants’ condition improves over
time (delayed treatment onset). We defined ‘long-term’ in the cur-
rent review as greater than six months post-intervention. Due to
the variability in long-term follow-up points, and the fact that
some studies assessed outcomes at multiple follow-up time points,
we subcategorised follow-up data into those that were measured
between six and nine months from baseline, and those that were
measured at 12 months. This allowed us to includedmultiple data
from single studies in order to assess the time course of depressive
symptoms and remission rates more stringently.
Search methods for identification of studies
Electronic searches
CCDAN’s Specialised Register (CCDANCTR)
The Cochrane Depression, Anxiety and Neurosis Group (CC-
DAN)maintain two clinical trials registers at their editorial base in
Bristol, UK; a references register and a studies-based register. The
CCDANCTR-References Register contains over 30,000 reports
of RCTs for depression, anxiety and neurosis. Approximately 65%
of these references have been tagged to individual, coded trials.
The coded trials are held in the CCDANCTR-Studies Register
and records are linked between the two registers through the use
of unique study ID tags. Coding of trials is based on the EU-Psi
coding manual. (Please contact the CCDAN Trials Search Co-
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ordinator for further details). Reports of trials for inclusion in
the Group’s registers are collated from routine (weekly), generic
searches ofMEDLINE (1950-), EMBASE (1974-) and PsycINFO
(1967-); quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL) and review specific searches of ad-
ditional databases. Reports of trials are also sourced from inter-
national trials registers c/o the World Health Organization’s trials
portal (ICTRP), drug companies, the handsearching of key jour-
nals, conference proceedings and other (non-Cochrane) system-
atic reviews and meta-analyses.
Details of CCDAN’s generic search strategies can be found on the
Group‘s website.
The Trials Search Co-ordinator searched the CCDANCTR to 11
November 2011, using the following terms:
CCDANCTR-Studies Register:
Diagnosis = Depression or Dysthymia or “Adjustment Disorder*”
or “Mood Disorder*” or “Affective Symptoms”
And
Age = Child or Adolescent
The Trials Search Co-ordinator searched the CCDANCTR-Ref-
erences Register using a more sensitive set of free-text terms to
identify additional untagged/uncoded references:
((depress* or dysthymi* or “adjustment disorder*” or “mood dis-
order*” or “affective symptom*”) and (child* or infant* or juvenil*
or minors or pediatri* or paediatri* or adolesc* or pubescen* or
puberty or teen* or young or youth* or school* or high-school or
college or student* or undergrad*))
Additional searches
We performed complementary searches on the following biblio-
graphic databases to April 2011 (after which we decided to rely on
the CCDAN specialised register alone, given the regular, generic
searches of these databases by the Trials Search Co-ordinator).
• MEDLINE (1996 to April 2011)
• EMBASE (1980 to April 2011)
• PsycINFO (1967 to April 2011)
Searching other resources
Reference list
We checked the reference lists of all included trials retrieved from
the searches to identify additional published or unpublished re-
search.
Personal communication
We contacted the authors of all included studies and recognised
experts in the field to ensure no study was missed (published or
unpublished).
Data collection and analysis
Selection of studies
Three review authors (PC, SH and GC) independently conducted
the screening process of titles and abstracts. We noted the trials
that appeared to fulfil the selection criterion and subsequently re-
trieved the full articles. The same review authors assessed full ar-
ticles for adherence to selection criteria. We have provided justifi-
cation for exclusion of trials for which full copies were retrieved.
To be included in the initial screen, references had to pass the fol-
lowing simple criteria.
• It had to be a RCT.
• Include participants with a diagnosis of a depressive
disorder using DSM or ICD criteria (as diagnosed by a clinician).
• At a minimum, compare an antidepressant medication with
a psychological therapy.
If discrepancies arose, we reached consensus through discussion,
with the aid of a fourth review author, if needed.
Data extraction and management
Two review authors (PC and GC) independently extracted pri-
mary and secondary outcome-related data from full articles and
recorded data on hard copy data collection forms. When disagree-
ment arose, consensus was reached following discussion, with the
aid of a third review author (SH), where necessary. Where required
data were not present or were in a form that was not compatible
with our meta-analysis, we attempted to contact the authors to
obtain or clarify data.
Main comparisons made in the review.
1. Psychological therapies alone versus antidepressant
medication alone.
2. Combination therapy versus psychological therapies alone.
3. Combination therapy versus antidepressant medication
alone.
4. Combination therapy versus psychological therapies plus
pill placebo.
A further two comparisons were possible given the inclusion cri-
teria (although no data were available for these comparisons).
1. Combination therapy versus antidepressant medication
plus psychosocial/attention only placebo.
2. Combination therapy versus ’treatment as usual’.
Assessment of risk of bias in included studies
Two independent review authors (PC andGC) conducted ’Risk of
bias’ assessment based on Chapter 8 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We discussed
discrepancies in rating and reached consensus, with the aid of a
third review author (SH) where necessary. We assessed risk of bias
as “low risk”, “unclear risk”, or “high risk”, in accordance with the
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updated guidance and software fromTheCochrane Collaboration
for the following domains.
1. Sequence Generation.
2. Allocation concealment.
3. Blinding of participants, personnel, and outcome assessors.
4. Incomplete outcome data.
5. Selective outcome reporting.
6. Other sources of bias.
We included all studies meeting the inclusion criteria, regardless
of the outcome of the assessment of risk of bias.
Measures of treatment effect
We entered data from collection forms into Review Manager 5
(RevMan 2011).We calculated odds ratios (ORs) with 95% confi-
dence intervals (CIs) for dichotomous outcomes such as remission,
and suicide-related outcomes. With regards to continuous scales,
there were many types of depression measures utilised in trials and
therefore we used the standardised mean difference (SMD) with
95% CIs to calculate treatment effects in comparisons containing
different assessment scales. In some cases, the same scales were
used across studies, and on these occasions, we used the mean dif-
ference (MD).
Unit of analysis issues
Where a study had more than one active treatment arm, we ex-
tracted data from the appropriate arm for each of our main com-
parisons.
For future updates where we will consider including cluster-RCTs
and cross-over RCTS, given the potential for carry-over affects,
particularly for psychological interventions, we will only include
the first phase of data from cross-over trials in any analysis.
For studies using a clustered randomisation method, if not re-
ported, we will contact trial authors to obtain the intracluster cor-
relation coefficient (ICC) for the sample. If we are unable to obtain
this information from the authors, we will use an ICC estimate
based on the average of the ICCs obtained from the other stud-
ies included in the analysis, or if necessary from relevant external
studies. We will then adjust the study population numbers to take
into account the effect of the clustering. We will undertake sen-
sitivity analysis to check the robustness of the data, and to make
decisions about which ICC adjustment to include in the data.
Dealing with missing data
Missing statistics
We obtained missing data from trial authors wherever possible.
In some cases, dichotomous outcomes such as remission rates,
were reported as percentages (Bernstein 2000; Clarke 2005). We
converted these percentages into dichotomous outcomes using
information regarding the total (N) in the analysis reported in the
publication. Where applicable, we contacted authors to confirm
we had calculated the raw numerator and denominator correctly.
In one case (Riggs 2007), only the standard error was reported for
continuous outcome measures. We calculated the standard devia-
tion for each group mean based on the sample size and standard
error and have documented this as appropriate.
Missing participants
For continuous outcomes, if available, we extracted intention-to-
treat (ITT) data and noted the method used for imputing missing
data in the ’Risk of bias’ table for each individual trial.
For remission by clinical interview, data were often reported for
’observed cases’ (OC) only (Melvin 2006; TADS 2004). In this
case we used the numbers randomised in an ITT analysis (making
the assumption that those who dropped out did not improve) and
compared this with an analysis based on the OC data provided as
a sensitivity analysis. In one case (Clarke 2005), remission rates
based on a cut-off score were reported based on an ITT analysis.
This study was the only one that contributed data to the compar-
ison, and we included these data.
Assessment of heterogeneity
We assessed heterogeneity on the basis of the Handbook’s recom-
mendations (I2 values of 0 to 40%: might not be important; 30%
to 60%: may representmoderate heterogeneity; 50% to 90%: may
represent substantial heterogeneity; and 75% to 100%: represents
considerable heterogeneity). Because the importance of the ob-
served I2 statistic depends on (i) magnitude and direction of ef-
fects and (ii) strength of evidence for heterogeneity, in addition
to the I2 value (Higgins 2003), we have presented the χ2 and its
P value and have considered the direction and magnitude of the
treatment effects in assessing heterogeneity. Because the χ2 test
is underpowered to detect heterogeneity in meta-analysis that in-
cludes only a few studies, a P value of 0.10 is used as a threshold
of statistical significance.
Assessment of reporting biases
We had planned to assess small study effects and potential publi-
cation bias using a funnel plot if 10 or more studies were included
in the meta-analysis, however, given we had so few trials we did
not do this. We assessed selective reporting of outcomes using the
’Risk of bias’ tool and have reported this in the ’Risk of bias’ tables.
Data synthesis
For all meta-analyses, we used a random-effects model (der
Simonian 1986). The random-effects method incorporates an as-
sumption that the different studies are estimating different, yet
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related, intervention effects, (which we were anticipating, partic-
ularly given the inclusion of different psychotherapy and medica-
tion interventions).
Subgroup analysis and investigation of heterogeneity
It was our intention to conduct separate analyses on the subgroups
below.
1. Children (six to 12 years) and adolescents (13 to 19 years).
2. Severity of illness (severe, moderate, or mild).
Sensitivity analysis
We intended to conduct the sensitivity analyses below to investi-
gate the effect that different statistical analyses may have exerted
on the effect size.
• Using observed case (OC) data (excluding studies which
use Last Observation Carried Forward (LOCF)).
• Excluding trials with ’no’ or ’unclear’ ratings for allocation
concealment.
Timeline
We will update this review in accordance with Cochrane Collab-
oration guidelines for updating.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
We retrieved 10,413 references from electronic searches to April
2011. One review author (PC) screened the titles and abstracts of
these references against inclusion and exclusion criteria. Of these,
we retained 89 and retrieved the full-text of each study. Two au-
thors (PC and SH) screened the full-text of 89 references. We
included, excluded and consolidated references into studies. We
included a total of nine studies in the review.
We conducted an updated search on the CCDANCTR (11
November 2011), retrieving 428 references. Two authors (PC and
GC) screened these references and retrieved the full-text of 18 ref-
erences, of which we included one in the review. We screened a
total of 10,841 references, from which we retrieved 51 full-text
articles, and included ten studies in the analyses.
Included studies
Eight of the ten trials were undertaken in the USA (Bernstein
2000; Clarke 2005; Cornelius 2009; Deas 2000; Mandoki 1997;
Riggs 2007; TADS 2004; TASA 2009); one in the UK (ADAPT
2007) and one in Australia (Melvin 2006). There were eight trials
of selective serotonin reuptake inhibitors (SSRIs) (ADAPT 2007;
Clarke 2005; Cornelius 2009; Deas 2000; Melvin 2006; Riggs
2007; TADS 2004; TASA 2009), one of a tricyclic antidepressant
(TCA) (Bernstein 2000) and one of a serotonin-norepinephrine
reuptake inhibitor (SNRI) (Mandoki 1997). Themajority of trials
contained two comparison arms, two trials contained three arms
(Melvin 2006; TASA 2009) and one contained four comparison
arms (TADS 2004). The TADS 2004 trial implemented a placebo
arm for the first stage of intervention (up to 12 weeks), after which
the placebo group were unblinded to condition, and offered an
alternative treatment. As a result, all follow-up data after 12 weeks
are based on three comparison conditions.
Five trials compared combination therapy to psychological ther-
apies with placebo medication (Bernstein 2000; Cornelius 2009;
Deas 2000; Mandoki 1997; Riggs 2007); four trials com-
pared combination therapies to antidepressant medication alone
(ADAPT 2007;Melvin 2006; TADS 2004; TASA 2009); one trial
compared combination therapy to a placebo condition (TADS
2004) and one compared combination therapy to ’treatment as
usual’, involving routine medication of SSRIs (Clarke 2005). In
the three trials with more than two comparison arms, psycho-
logical therapy alone was compared to antidepressant medication
alone and a combination of medication and psychological therapy
(Melvin 2006; TADS 2004; TASA 2009).
Therefore for objective one there were three trials that had rel-
evant psychological therapy alone and medication alone arms
(Melvin 2006; TADS 2004; TASA 2009), although TASA 2009
did not contribute any data. For objective two there were four
trials that included a combination therapy and medication alone
arms (ADAPT 2007; Clarke 2005; Melvin 2006; TADS 2004),
each of which contributed some data to some outcomes. For ob-
jective three, two studies included combination therapy and psy-
chological therapy alone arms, and both contributed data (Melvin
2006; TADS 2004), and five studies included combination ther-
apy and psychological therapy plus placebo arms (Bernstein 2000;
Cornelius 2009; Deas 2000; Mandoki 1997; Riggs 2007); only
Mandoki 1997 contributed no data to any outcome.
Participants
One trial involved children and adolescents aged eight to 17 years
(Mandoki 1997), and nine contained adolescents over the age of
11 years. Five trials had an age range of between11or 12 to17or 18
years (ADAPT 2007; Bernstein 2000; Clarke 2005;Melvin 2006;
TADS 2004 TASA 2009); one between 13 and 19 years (Riggs
2007); one between 15 and 18 years (Deas 2000) and one slightly
older sample of 15 to 20 years (Cornelius 2009). The mean age
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ranged from12.7 years to 17.6 years. Three trials contained similar
proportions of males and females (Bernstein 2000; Cornelius
2009; TADS 2004), three contained around three times as many
females as males (ADAPT 2007; Clarke 2005; TASA 2009), and
three contained around twice as many males as females (Deas
2000; Mandoki 1997; Riggs 2007).
Nine trials included participants with major depressive disorder
(MDD), with diagnoses made on either DSM-III or DSM-IV cri-
teria, deduced from structured interviews such as the K-SADS-
PL. Deas 2000 used both the K-SADS and the HAM-D to mea-
sure baseline depression severity. Two trials used a cut-off score
of 35 or 36 on the CDRS-R (Bernstein 2000; TASA 2009), and
TADS 2004 used a higher cut-off score of 45 on the CDRS-R to
determine eligibility. One trial used a cut-off of eight or more on
the Health of the Nation Outcome scales for children and adoles-
cents (HoNOSCA; ADAPT 2007). Baseline severity of depressive
symptoms was measured using the CDRS-R in six trials (ADAPT
2007; Bernstein 2000; Mandoki 1997; Riggs 2007; TADS 2004;
TASA 2009), theCES-D in one trial (Clarke 2005) and theHAM-
D in two trials (Cornelius 2009; Deas 2000). Melvin 2006 re-
ported baseline severity split by depressive diagnosis as determined
by the K-SADS. Three of the six trials that measured baseline
severity using the CDRS-R (ADAPT 2007; Riggs 2007; TASA
2009) reported mean t-scores that ranged from 73.03 to 76.14.
It should be noted that while studies of young people with treat-
ment resistant depressionwere excluded, in theADAPT 2007 trial,
an early description of the study methodology described its aim
as treating “persistent adolescent major depression” (Harrington
2002) with entry criteria being a failure to respond, in the initial
phase of the trial, to two brief initial sessions of support and edu-
cational interventions with a psychiatrist. The sample included 34
adolescents with “proven non-response” in that they had failed a
trial of psychosocial intervention before being referred to the trial.
This was a pragmatic trial conducted in tertiary specialist mental
health outpatient clinics and the authors note that “Most partici-
pants had already been treated and would have received psychoso-
cial interventions before medication” (pg. 4 ADAPT 2007).
Four studies reported data on the proportion or percentage of
young people who experienced any comorbid disorder (ADAPT
2007; Melvin 2006; TADS 2004; TASA 2009). In these tri-
als, dysthymic disorders, anxiety disorders, and disruptive be-
havioural disorders (Oppositional Definant Disorder (ODD) /
Conduct Disorder (CD)) were the most common comorbid con-
ditions. Bernstein 2000 reported the rate of comorbid anxiety, as
it was part of the trial’s inclusion criteria that participants were
experiencing a current anxiety disorder, and major depressive dis-
order based on DSM-III-R criteria. The study by Riggs 2007 in-
cluded participants with comorbid substance use disorder, and
lifetime conduct disorder, while all participants in Deas 2000 and
Cornelius 2009 had a dual diagnosis of major depression and an
alcohol use disorder; however, no other comorbid disorders were
measured in either trial. The majority of trials excluded partici-
pants based on certain comorbid conditions; however, one trial
did not report data on any excluded comorbid conditions (Deas
2000). All but one of the trials excluded participants on the ba-
sis of psychotic features or disorders (Bernstein 2000). Pervasive
developmental disorders, general intellectual disabilities or men-
tal retardation were excluded in seven trials, and bi-polar disor-
der, either past or present, in seven trials. Those with substance
abuse or dependence were excluded in four trials (Bernstein 2000;
Cornelius 2009; Melvin 2006; TASA 2009), those with conduct
disorder in two trials (Bernstein 2000; TADS 2004), and those
with attention deficit hyperactivity disorder (ADHD) or an eating
disorder in one trial (Bernstein 2000).
Participants whowere ’actively suicidal’ were excluded in two trials
(Mandoki 1997; TADS 2004). Three trials included participants
who reported high levels of suicidal behaviour (Clarke 2005;
Melvin 2006;Riggs 2007), however, these trials still excluded those
who were ’actively suicidal’ or likely to make a suicide attempt
during the course of the trial. The ADAPT 2007 trial included
participants who were actively suicidal, and a prerequisite of the
TASA 2009 trial, was that participants hadmade a suicide attempt
within the past 90 days. Five of these studies measured suicidal
behaviour at baseline (ADAPT 2007; Melvin 2006; Riggs 2007;
TADS 2004; TASA 2009).
Please see Characteristics of included studies for details by indi-
vidual study.
Interventions
Treatment programmes ranged from sixweeks (Clarke 2005) to 24
weeks in length (TASA 2009), and participants received between
six and 24 sessions of psychological therapy. After an acute phase
of treatment, four trials described a continuation or maintenance
phase, or both. In two trials, participants were offered ’booster
sessions’, that were less frequent (ADAPT 2007; Melvin 2006).
Clarke 2005 stated that proceeding onto the second module of
their cognitive behavioural therapy (CBT) treatment was based
on “the degree of youth recovery from depression, enduring youth
problems other than depression, and/or to consolidate gains”. The
trial also contained a ’continuation phase’, whereby young people
received a brief telephone ’check-in’ by their therapists at one,
two, three, five, seven, and nine months after completing the acute
phase. The TADS 2004 trial was divided into three stages; stage
one: up to 12 weeks; stage 2: up to 18 weeks; and stage 3: up to
36 weeks. Participants in the placebo group were unblinded after
stage one and offered either telephone follow-up, or their choice of
treatment. Participants in the CBT alone, and CBT + fluoxetine
groups received weekly CBT sessions up to stage one. In stage two
participants were further defined as either ’partial responders’ or
’full responders’. Partial responders received six additional CBT
sessions and full responders, three (biweekly) sessions. At stage
three, participants in both treatment arms received CBT once
every six weeks.
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All psychological therapies contained core elements of CBT, or
behavioural therapy (BT), or both, such as cognitive restructuring,
goal setting and pleasant events scheduling. The TASA 2009 study
consisted of a CBT-suicide prevention (CBT-SP) programme, in
which known risk factors for suicidal behaviour, such as depression
were addressed. The CBT-SP programme included ’chain analysis
of the index suicide attempt’ and safety planning to reduce current
suicide risk. Clarke 2005 allowed participants to choose one of two
therapy approaches to try first; either cognitive restructuring or be-
havioural activation; 67.5% of participants chose behavioural ac-
tivation. Some programmes had a primary focus on another disor-
der, with depression being addressed as a secondary aim. Bernstein
2000 employed a CBT programme based on a school refusal treat-
ment programme by Last 1998, which centred around negative
thoughts surrounding school, and ’behavioural contracting’ to in-
crease school attendance. Cornelius 2009 utilised CBT for the
treatment of adolescent depression, described by Brent 1997 in
addition to motivational enhancement therapy (MET) described
inMiller 1992 for the treatment of alcohol use disorders. The trial
by Riggs 2007 focused on substance abuse, and contained one
module on the management of depression, and how the identifi-
cation of negative mood states could trigger substance abuse. The
majority of the studies were manualised; two trials did not give
any information (Clarke 2005; Mandoki 1997) and one was non-
manualised (Deas 2000).
In nine trials the therapy included individual CBT sessions, and
in one trial there were group sessions (Deas 2000). Three trials
formally included youth-parent sessions (Bernstein 2000; Melvin
2006;TADS2004;TASA2009), while others encouragedparental
involvement outside of the therapy sessions themselves (ADAPT
2007). Clarke 2005 held parent meetings for reviewing the gen-
eral topics given in therapy sessions. Three trials included fidelity
checks on therapists’ adherence to protocol by video/audio taping
sessions rated by independent raters (ADAPT 2007; Clarke 2005;
Riggs 2007). Adherence was high, at over 80%. CBT sessions
were delivered by a variety of professionals including a psychia-
trist (Deas 2000), a clinical psychologist (Bernstein 2000), mas-
ters level psychologists (Clarke 2005), a social worker with expe-
rience in CBT, a probationary psychologist and general medical
practitioners (Melvin 2006), study therapists trained by the man-
uals’ developers (Riggs 2007) and trained psychotherapists (TASA
2009).
Six trials administered SSRI treatment of either fluoxetine (
ADAPT 2007; Cornelius 2009; Riggs 2007; TADS 2004) or ser-
traline (Deas 2000; Melvin 2006). Bernstein 2000 used a TCA
(imipramine) and Mandoki 1997 used a SNRI (venlafaxine). Six
trials employed a flexible dosing scheme (ADAPT 2007; Bernstein
2000; Deas 2000; Melvin 2006; TADS 2004; TASA 2009). The
’treatment as usual’ condition in the Clarke 2005 study allowed
participants to receive antidepressant medication prescribed ei-
ther by the HealthMaintenance Organisation or outside agencies;
therefore dosage and medication type varied on an individual ba-
sis.
Please see Characteristics of included studies for details by indi-
vidual study.
Outcomes
There were three primary outcomes of this review; remission of
a depressive disorder according to a clinical interview by a men-
tal health professional; acceptability of treatment as measured by
dropouts; and suicide-related serious adverse outcomes. Remiss-
sion in these three trials was determined by the K-SADS scale
(Clarke 2005; Melvin 2006; TADS 2004). Only in Melvin 2006
was it clear that DSM-IV criteria for full remission were used.
Suicide-related SAEs were reported in the TADS 2004 trial as
’spontaneously reported suicide-related events’, andweremeasured
using the Columbia Classification Algorithm of Suicide Assess-
ment. ADAPT 2007 measured suicidal acts using the K-SADS-PL
depression section, and Melvin 2006 reported adverse outcomes
from the trial but did not state the criteria they used. Riggs 2007
measured suicidality using question 13 on the CDRS-R.
In most trials remission from depressive disorder was defined as a
drop below a predetermined cut-off on a continuous measure of
symptoms. A cut-off score of ≤ 28 on the CDRS-R scale was used
in three studies (Riggs 2007; TADS 2004; TASA 2009), while
a more liberal cut-off of ≤ 35 was used by Bernstein 2000, and
Clarke 2005 used a score of ≤ 15 on the Centre for Epidemiolog-
ical Studies-Depression (CES-D) scale.
All six trials which included a clinician rating of depressive symp-
tom severity, used the CDRS-R. A variety of tools were used to
measure self rated depressive symptom severity, including the Beck
Depression Inventory (BDI) (Bernstein 2000; Cornelius 2009;
TASA 2009), Reynolds Adolescent Depression Scale (RADS)
(Melvin 2006; TADS 2004), Mood and Feelings Questionnaire
(MFQ) (ADAPT 2007), CES-D (Clarke 2005), and HAM-D
(Deas 2000).
The most common measure of functioning was the C-GAS
(ADAPT 2007; Clarke 2005; TASA 2009). The GAF (Melvin
2006) and Clinical Global Impression Improvement (CGI-I) scale
(Riggs 2007) were also used.
Melvin 2006 and TADS 2004 reported suicidal ideation as a con-
tinuous outcome using the SIQ-JR scale. TADS 2004 also re-
ported suicidal ideation as a dichotomous measure, defining par-
ticipants who scored above 31 on the SIQ-JR scale as displaying
the behaviour.
Missing outcome data
We successfully obtained further outcome data for the trials de-
scribed in Melvin 2006 and Riggs 2007. The trial authors for the
TADS 2004 study referred us to the National Institute of Mental
Health (NIMH), from whom no further information could be
obtained. The trial authors for Clarke 2005 and Cornelius 2009
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wrote that they were unable to provide us with further data. We
did not have any response from other trial authors.
Excluded studies
Of the 51 full-text articles retrieved, references were consoli-
dated into respective studies for which there were multiple refer-
ences (ADAPT 2007; Bernstein 2000; TADS 2004; TASA 2009;
TORDIA 2008), after which, we excluded 10 trials from the re-
view. We excluded seven trials as they did not contain an appropri-
ate comparison condition (Cheung 2008; Emslie 2002 (Eli 2002);
Findling 2008; Fristad 2009; King 2009; Tang 2009; Wagner
2003); one was not a RCT (Emslie 2004); one implemented a
cross-over design (Dujovne 1994); and we further excluded one
study as it contained a ’treatment resistant’ population (TORDIA
2008).
Risk of bias in included studies
The original intention was to conduct a sensitivity analysis on the
primary outcomemeasures, excluding trials with ’high risk’ or ’un-
clear risk’ ratings for allocation concealment. However, only four
trials were rated as such. One trial (TASA 2009) did not contain
any data suitable for meta-analysis, and the remaining three were
contained in comparisons with only limited data, therefore we did
not conduct a sensitivity analysis. We have summarised and de-
scribed all risk of bias items in Figure 1.
Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Allocation
Of the 10 included studies, five reported sufficient information
to determine that adequate methods of sequence generation were
used (Clarke 2005; Cornelius 2009; Deas 2000; Melvin 2006;
TADS 2004). There were three in which the sequence generation
methods were rated as not being adequate (Bernstein 2000; Riggs
2007; TASA 2009). Adequate sequence generation was rated as
’unclear’ in two trials (ADAPT 2007; Mandoki 1997).
The allocation of intervention arms were judged to be concealed
in four trials (ADAPT 2007; Deas 2000; Riggs 2007; TADS
2004). TASA 2009 did not adequately conceal allocation, while
the remaining five trials (Bernstein 2000; Clarke 2005; Cornelius
2009; Mandoki 1997; Melvin 2006) did not contain adequate
information to determine whether allocation to intervention arms
was concealed.
Blinding
Six trials contained sufficient information to determine that out-
come assessors were blind to the intervention group of participants
(ADAPT 2007; Bernstein 2000; Clarke 2005; Mandoki 1997;
TADS 2004; TASA 2009). There was insufficient information to
determine blinding of outcome assessors in two trials (Deas 2000;
Riggs 2007), while the remaining two trials did not use blinded
outcome assessors (Cornelius 2009; Melvin 2006).
Two studies tested psychotherapy alone against medication alone.
In TADS 2004, in which a total of four arms were included,
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the psychotherapy was not blinded (one arm received cognitive
behavioural therapy (CBT) alone and one arm received CBT and
fluoxetine), but themedication armwas blinded (one arm received
fluoxetine alone and one arm received placebo alone). In Melvin
2006 there were only three arms in total: one CBT alone, one
sertraline alone, and one a combination of these; there was no
medication placebo arm or placebo psychotherapy arm.
Therefore, in these two studies, which also testedmedication alone
against combination therapy, the psychotherapy was not blind.
In two further studies testing this combination (ADAPT 2007;
Clarke 2005) the psychotherapy was not blinded.
For studies testing the efficacy of psychotherapy alone against com-
bination therapy, in five studies a placebo pill was used and par-
ticipants were blind to medication intervention (Bernstein 2000;
Cornelius 2009; Deas 2000; Mandoki 1997; Riggs 2007). In two
studies testing this combination a placebo pill was not used in the
psychotherapy condition (Melvin 2006; TADS 2004).
In one study, after an initial period of randomisation, participants
selected the treatment arm they preferred (TASA 2009).
Melvin 2006 was the only study in which outcome assessment was
not clearly blinded.
Incomplete outcome data
Nine of ten trials addressed incomplete data including descrip-
tion of ITT analyses and recording and explanation of partici-
pant dropouts adequately (ADAPT 2007; Bernstein 2000; Clarke
2005; Cornelius 2009; Deas 2000; Melvin 2006; Riggs 2007;
TADS 2004; TASA 2009) while this was not adequately addressed
in one trial (Mandoki 1997).
There was unbalanced drop out in two trials (Melvin 2006; TADS
2004) and reasons for dropout were not reported in three trials
(Clarke 2005; Cornelius 2009; Deas 2000).
Selective reporting
Four trials were judged to have been free of selective reporting
(ADAPT 2007; Cornelius 2009; Deas 2000; TADS 2004). We
were unclear whether there was selective reporting in three trials
(Bernstein 2000; Clarke 2005; Melvin 2006), as some trial out-
comeswere only reported at particular time points, orwere difficult
to interpret. Clarke 2005 reported using an ITT analysis, however
whenwe didmanual calculations for remission rates we found that
remission was analysed for observed cases only. Mandoki 1997
was judged to have selective reporting, as the results contained no
numerical data and all outcomes were presented in graph format.
TASA 2009 also reported only selected data, providing results for
the combination treatment group and overall results, but not for
other comparison arms.
Other potential sources of bias
Five trials were determined to be free of additional sources of bias
(ADAPT 2007; Cornelius 2009; Mandoki 1997; Melvin 2006;
Riggs 2007). Clarke 2005 reported that telephone administration
of self report measures may have created bias.
Effects of interventions
We report on results by objectives (one to three) with each rele-
vant comparison for each objective listed. We do not report on
heterogeneity for non-significant results.
Are psychological therapies or antidepressant medication
more effective?
Data relevant to this research question are contained within the
analyses undertaken in comparison 1.
Comparison 1: Psychological therapy versus antidepressant
medications
Two studies (n = 220) compared psychological therapies versus
antidepressant medication (Melvin 2006; TADS 2004) and con-
tained data suitable for this comparison.
1.1 to 1.4: Remission from depressive disorder by clinical
interview
Both studies (Melvin 2006; TADS 2004) reported remission rates
based on observed case data. We undertook analysis based on
numbers randomised in the first instance .
• At post-intervention the effect of antidepressants on the
rate of remission was unclear (OR 0.62, 95% CI 0.28 to 1.35)
Analysis 1.1. When observed case data was evidence of a small
effect in favour of antidepressants (OR 0.52, 95% CI 0.27 to
0.98) Analysis 1.2. There was a large dropout from the CBT
group in the TADS 2004 trial (28%), compared to the Melvin
2006 trial (5%); whereas at 6-9 months follow-up the dropout
from the medication group in the TADS 2004 trial was 20%
compared with 19% in the Melvin 2006 trial.
• One trial (n = 20) reported data for six to nine months
follow-up (Melvin 2006) Analysis 1.3. The effect of taking
medication compared with psychological therapy was unclear
(OR 0.83, 95% CI 0.27 to 2.60) and there was little difference
in the outcome when OC data was used (OR 0.67, 95% CI 0.18
to 2.49) Analysis 1.4.
• No trial provided data on remission at 12 months follow-
up.
1.5 and 1.6: Dropouts
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Both studies (Melvin 2006; TADS 2004) reported the number of
dropouts during the intervention.
• At post-intervention, the effect on dropout of receiving
psychological therapy compared with receiving antidepressant
medication was unclear (OR 0.61, 95% CI 0.11 to 3.28)
Analysis 1.5.
• At six to nine months follow-up there continued to be an
unclear effect on dropout rates across the two treatment
conditions (OR 1.17, 95% CI 0.63 to 2.19) Analysis 1.6.
• No trial provided data on dropouts at 12 months follow-up.
Suicide-related SAEs
TADS 2004 also reported on ’spontaneously reported suicide-re-
lated events’, measured using the Columbia Classification Algo-
rithm of Suicide Assessment. At post-intervention, 10 out of 109
participants in the medication treatment arm had experienced a
suicide-related event; this included two suicide attempts, and eight
instances of suicidal ideation. Five out of 111 participants receiv-
ing psychological therapy reported a suicidal event, of which one
was a suicide attempt, and four were suicidal ideation.
The TADS 2004 trial also reported on the total number of suicide-
related events that occurred up to the 36-week follow-up point.
Sixteen out of 109 participants who received medication experi-
enced a suicide-related event during the entire trial, and seven out
of 111 participants in the psychological therapy arm experienced
a suicide-related event.
1.7 to 1.11 Suicide-related outcomes
TADS 2004 reported dichotomous data regarding suicidal
ideation, as defined by a score of more than 31 on the SIQ-JR.
• At post-intervention (n = 188) there were significantly
fewer participants experiencing suicidal ideation in the
psychological therapy group than in the medication group (OR
0.26, 95% CI 0.09 to 0.72) Analysis 1.7.
• At six to nine months follow-up, this effect was still evident
(OR 0.26, 95% CI 0.07 to 0.98) Analysis 1.8.
• There were no data available for 12 months follow-up.
Two trials (Melvin 2006; TADS 2004) reported continuous sui-
cidal ideation data, and used the SIQ-JR.
• At post-intervention, there was a small effect favouring
psychological therapy compared with medication (MD -3.12,
95% CI -5.91 to -0.33) Analysis 1.9.
• The effect remained at six to nine months follow-up (MD -
2.89, 95% CI -5.49 to -0.28) Analysis 1.10.
• Only one trial (TADS 2004) provided data at 12 months
follow-up. The reduction in suicidal ideation experienced by
those receiving psychological therapy did not reach statistical
significance (MD -2.50, 95% CI -5.09 to 0.09) Analysis 1.11.
1.12 to 1.14 Remission from depressive disorder by cut-off
One trial (TADS 2004) reported data regarding remission from
depressive disorder by cut-off score, using an upper threshold of
< 28 on the CDRS-R scale.
• At post-intervention, the effect on remission rates of
receiving medication or psychological therapy was unclear (OR
0.65, 95% CI 0.33 to 1.28) Analysis 1.12.
• The effect remained unclear at six to nine months follow-
up (OR 1.50, 95% CI 0.88 to 2.58) Analysis 1.13.
• It was also unclear at 12 months follow-up (OR 0.84, 95%
CI 0.49 to 1.47) Analysis 1.14.
1.15 to 1.17 Depressive symptoms: Clinician rated
Data on clinician rated depression symptoms were only available
for the TADS 2004 trial (n = 220), and were measured using the
CDRS-R.
• At post-intervention, there was evidence of a small effect on
CDRS-R scores for those receiving medication, compared with
those receiving psychological therapy (MD 5.76, 95% CI 3.46
to 8.06) Analysis 1.15.
• At six to nine months follow-up, the effect of receiving
medication or psychological therapy was unclear (MD 0.05,
95% CI -2.11 to 2.21) Analysis 1.16.
• At 12 months follow-up, the effect remained unclear (MD
0.90, 95% CI -0.93 to 2.73) Analysis 1.17.
1.18 to 1.20 Depressive symptoms: Self rated
Two trials provided data for this outcome (Melvin 2006; TADS
2004), with a total of 144 participants.
• At post-intervention, the effect on self reported depressive
symptoms of receiving medication or psychological therapy was
unclear (SMD 0.16, 95% CI -0.69 to 1.01) Analysis 1.18. There
was a difference in the direction of the effect of the interventions
in the two trials included in the meta-analysis (and considerable
heterogeneity between the trials (I2 = 81%, P = 0.02)), with
Melvin 2006 favouring psychological therapy, and TADS 2004
favouring medication.
• At six to nine months follow-up, the effect remained
unclear (SMD -0.04, 95% CI -0.51 to 0.42) Analysis 1.19, and
heterogeneity between them was non-significant (I2 = 57%, P =
0.13).
• At 12 months follow-up, only TADS 2004 had suitable data
for meta-analysis and the effect of medication or psychological
therapy on levels of self reported depressive symptoms remained
unclear (MD 0.50, 95% CI -2.74 to 3.74) Analysis 1.20.
1.21 and 1.22 Functioning
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One trial assessed functioning in this comparison (Melvin 2006).
• At post-intervention (n = 42) the effect of medication
compared with psychological therapy in improving functioning
was unclear (MD 2.19, 95% CI -3.36 to 7.74) Analysis 1.21.
• The effect remained unclear at six to nine months follow-
up (MD -0.39, 95% CI -6.66 to 5.88) Analysis 1.22.
• No data were available for 12 months follow-up.
Is combination therapy more effective than antidepressant
medication?
Data relevant to this research question are contained within the
analyses undertaken in comparison 2.
Comparison 2: Combination therapy versus antidepressant
medication
Four studies (n = 618) provided useable data for this comparison
(ADAPT 2007; Clarke 2005; Melvin 2006; TADS 2004).
2.1 to 2.5 Remission from depressive disorder by clinical
interview
Three studies reported data on rates of remission by clinical in-
terview (Clarke 2005; Melvin 2006; TADS 2004). The Melvin
2006 and TADS 2004 trials reported observed case data. We used
numbers randomised in the analysis in the first instance.
• At post-intervention, based on data from three trials with
419 participants (Clarke 2005; Melvin 2006; TADS 2004), there
was an effect on remission rates favouring combination therapy
that did not reach significance compared with those who
received medication alone (OR 1.50, 95% CI 0.99 to 2.27)
Analysis 2.1. There was little difference in outcome when OC
data were used (three trials; 378 participants; OR 1.56, 95% CI
0.98 to 2.47) Analysis 2.2.
• At six to nine months follow-up, data from two trials with
265 participants (Clarke 2005; Melvin 2006) again showed some
effect of combination therapy that did not reach significance
(OR 1.93, 95% CI 0.93 to 4.00) Analysis 2.3, with no real
change in outcome when OC data were used (OR 1.94, 95% CI
0.88 to 4.27) Analysis 2.4.
• At 12 months, only one trial had data suitable for meta-
analysis (Clarke 2005). The effect of the intervention was in the
opposite direction, favouring medication alone, however this
effect was small and did not reach significance (OR 0.49, 95%
CI 0.14 to 1.69) Analysis 2.5.
2.6 to 2.8 Dropouts
Four studies provided data concerning dropouts at post-interven-
tion and three to six months follow-up (ADAPT 2007; Clarke
2005; Melvin 2006; TADS 2004).
• At post-intervention (n = 627) the effect of combination
therapy compared with medication alone was unclear (OR 0.89,
95% CI 0.49 to 1.63) Analysis 2.6.
• At three to six months (n = 420) there appeared to be no
difference between the two treatment approaches (OR 0.94,
95% CI 0.54 to 1.64) Analysis 2.7.
• At 12 months only one study provided data (Clarke 2005),
with significantly fewer participants dropping out from
medication alone, compared with combination therapy (OR
2.42, 95% CI 1.05 to 5.59) Analysis 2.8.
Suicide-related SAEs
At post-intervention, TADS 2004 reported that six out of 107
participants in the combination therapy group experienced a sui-
cide-related event; two were suicide attempts, one act was of un-
known intent, and three participants reported suicidal ideation.
For participants in the medication alone group, 10 out of 109
experienced an event, with two being an attempt and eight being
episodes of suicidal ideation.
In total, nine out of 107 participants in the combination therapy
group experienced a suicidal event at any point during the study.
For participants in the medication alone group, 16 out of 109
experienced a suicidal event.
ADAPT 2007 measured suicidal acts using the K-SADS-PL de-
pression section. At 12 weeks, 8% of participants in the medi-
cation alone group reported attempting suicide, compared with
6.9% of the combination therapy group. At 28-week follow-up
6.4% of themedication alone group and 7.1% of the combination
therapy group had reported attempting suicide.
Melvin 2006 report that one participant in the combination ther-
apy group and four in the medication alone group attended treat-
ment sessions with ’high levels of suicidality’ (pg. 1159), however
no one had to discontinue treatment due to these symptoms, and
no suicidal behaviours were reported as part of the adverse events.
2.9 to 2.14 Suicidal-related behaviours
Dichotomous data from the ADAPT 2007 and TADS 2004 trials
were included in this analysis. ADAPT 2007 data is based on the
ideation outcome of the K-SADS-PL, and TADS 2004 is based
on a cut-off score of the SIQ-JR.
• At post-intervention, the effect of combination therapy
compared with medication alone is unclear (OR 0.75, 95% CI
0.26 to 2.16) Analysis 2.9. There was significant heterogeneity (I
2 = 68%, P = 0.08).
• At six to nine months follow-up, the effect of the two
intervention approaches remains unclear (OR 0.53, 95% CI
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0.06 to 4.58) Analysis 2.10. There was significant heterogeneity
(I2 = 83%; P = 0.08).
• Data at 12 months follow-up was only available from the
TADS 2004 trial, and this favoured combination therapy, with
fewer individuals reporting suicidal ideation, compared with
those treated with medication alone; however this did not reach
significance Analysis 2.11.
Two trials (Melvin 2006; TADS 2004) provided continuous sui-
cidal ideation data.
• There were no differences in treatment approaches post-
intervention (MD -2.57, 95% CI -5.53 to 0.40) Analysis 2.12,
at six to nine months (MD -1.89, 95% CI -4.50 to 0.72)
Analysis 2.13; or at 12 months follow-up (only TADS 2004
provided data for this time point) (MD -1.60, 95% CI -4.18 to
0.98) Analysis 2.14.
2.15 to 2.17 Remission from depressive disorder by cut-off
Data from one study (TADS 2004) containing 216 participants
was suitable for the post-intervention and six to nine months time
points, and is based on a CDRS-R score of less than 28. At 12
months follow-up, data from two studies was combined in a meta-
analysis (Clarke 2005; TADS 2004).
• At post-intervention, significantly more participants
receiving combination therapy were in remission compared with
those who received medication alone (OR 2.01, 95% CI 1.11 to
3.63) Analysis 2.15.
• At six to nine months follow-up, the effect of the two
treatment approaches is unclear (OR 0.90, 95% CI 0.53 to 1.53)
Analysis 2.16.
• The effect remains unclear at 12 months follow-up (OR
1.45, 95% CI 0.60 to 3.52) Analysis 2.17.
2.18 to 2.20 Depressive symptoms: Clinician rated
Two trials (ADAPT2007;TADS2004, 415participants) provided
data at post-intervention and six to nine months follow-up on
clinician rated depressive symptom scales.
• At post-intervention, the effect of combination therapy
compared to medication alone on clinician rated depressive
symptoms was unclear (MD -0.27, 95% CI -4.95 to 4.41)
Analysis 2.18. The direction of effect of the two trials included
in the meta-analysis was opposite (and there was significant
heterogeneity between the trials (I2 = 74%, P = 0.05)), with
TADS 2004 favouring combination therapy, and ADAPT 2007
favouring medication alone.
• At six to nine months follow-up, the effect of the two
interventions remained unclear (MD-0.27, 95% CI -2.26 to
1.72) Analysis 2.19.
• At 12 months follow-up data were only available from the
TADS 2004 trial, and the effect of the two treatment approaches
was unclear (MD -0.70, 95% CI -2.46 to 1.06) Analysis 2.20.
2.21 to 2.23 Depression symptoms: Self rated
Four trials were included in this analysis (ADAPT 2007; Clarke
2005; Melvin 2006; TADS 2004, 593 participants).
• At post-intervention, the effect of the two intervention
approaches on self reported depressive symptoms was unclear
(SMD -0.07, 95% CI -0.25 to 0.12) Analysis 2.21.
• The effect remained unclear at six to nine months follow-
up (SMD -0.06, 95% CI -0.28 to 0.17) Analysis 2.22.
• At 12 months, two trials with 368 participants provided
data for meta-analysis, and there was evidence of a small effect
favouring the use of combination therapy over medication alone
in producing lower levels of self reported depressive symptoms
(SMD -0.26, 95% CI -0.46 to -0.05) Analysis 2.23.
2.24 to 2.26 Functioning
Data regarding level of functioning was provided by three trials
(ADAPT 2007; Clarke 2005; Melvin 2006) at post-intervention
and six to nine months follow-up.
• At post-intervention (n = 396), the effect of receiving
combination therapy compared with medication alone was
unclear (SMD 0.09, 95% CI -0.11 to 0.28) Analysis 2.24.
• At six to nine months follow-up the effect remained unclear
(SMD 0.08, 95% CI -0.12 to 0.28) Analysis 2.25.
• Only data from the Clarke 2005 trial were available at 12
months follow-up; this showed a small effect favouring
combination therapy compared with medication alone (MD
3.00, 95% CI 0.40 to 5.60) Analysis 2.26.
Is combination therapy more effective than
psychological therapies
Data relevant to this clinical question are contained within the
analyses undertaken as part of comparisons 3 and 4. The most ap-
propriate trial design to answer this research question is the com-
parison between combination therapy and psychological therapies
plus placebo, contained in comparison 4.
Comparison 3: Combination therapy versus psychological
therapy
We included two trials for this comparison (Melvin 2006; TADS
2004).
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3.1 and 3.4 Remission from depressive disorder by clinical
interview
Both trials (Melvin 2006; TADS 2004) contained data on remis-
sion by clinical interview based on observed case data. We used
numbers randomised in the analysis.
• At post-intervention (n = 265), the effect of combination
therapy, compared with those who received psychological
therapy alone was unclear (OR 1.61, 95% CI 0.38 to 6.90)
Analysis 3.1 with no real change in outcome when OC data were
used (N = 222) (OR 1.82, 95% CI 0.38 to 8.68) Analysis 3.2.
The direction of effect of the two trials included in the meta-
analysis was opposite (there was significant heterogeneity
between the trials (I2 = 72%, P = 0.05)), with Melvin 2006
favouring psychological therapy alone and TADS 2004 favouring
combination treatment.
• At six to nine months follow-up, data from one study was
available for meta-analysis (Melvin 2006, 47 participants). The
effect favoured combination therapy but did not reach
significance (OR 2.55, 95% CI 0.78 to 8.36) Analysis 3.3 with
wider CIs when OC data used (OR 3.40, 95% CI 0.81 to 14.24)
Analysis 3.4.
• No study reported data at 12 months follow-up.
3.5 to 3.6 Dropouts
Two studies contained data suitable for this comparison (Melvin
2006; TADS 2004).
• At post-intervention, the effect of receiving combination
therapy compared with receiving psychological therapy alone was
unclear (OR 1.23, 95% CI 0.12 to 12.71) Analysis 3.5. The
direction of effect of the two trials included in the meta-analysis
was opposite (there was statistical heterogeneity between the
trials (I2 = 77%, P = 0.04)), with Melvin 2006 favouring
psychological therapy alone and TADS 2004 favouring
combination treatment.
• At six to nine months follow-up there appears to be no
difference in the rate of dropout between the two intervention
types (OR 0.75, 95% CI 0.40 to 1.42) Analysis 3.6.
• No data was available for meta-analysis at 12 months follow
up.
Suicide-related SAEs
In the TADS 2004 study, at post-intervention, 5.6% of partici-
pants in the combination group and 4.5% of participants in the
psychological therapy only group reported a suicide-related event.
During the 36-week study period, 8.4%of combination treatment
participants and 6.3% of psychological therapy only participants
had experienced a suicidal event.
3.7 to 3.11 Suicidal-related behaviours
Only TADS 2004 provided dichotomous suicidal ideation data,
at post-intervention, and six to nine months follow-up. Suicidal
ideation events were based on a cut-off score on the SIQ-JR.
• At post-intervention, there is little evidence of any
difference between treatment approaches (OR 1.68, 95% CI
0.53 to 5.34) Analysis 3.7.
• The effect is unclear at six to nine months follow-up (OR
0.63, 95% CI 0.10 to 3.89) Analysis 3.8.
Continous suicidal ideation data from Melvin 2006 and TADS
2004 were available for post-intervention and six to nine months
follow-up. Both used the SIQ-JR scale. At 12 months follow-up
only the TADS 2004 study was available.
• There appears to be little effect of either intervention in
level of suicidal ideation at post-intervention (MD 0.60, 95% CI
-2.25 to 3.45) Analysis 3.9, six to nine months follow-up (MD
1.78, 95% CI -2.29 to 5.85) Analysis 3.10or 12 months follow-
up (MD 0.90, 95% CI -1.37 to 3.17) Analysis 3.11.
3.12 to 3.14 Remission from depressive disorder by cut-off
One trial (TADS 2004) reported data for remission from depres-
sive disorder utilising a CDRS-R cut-off of less than 28.
• At post-intervention, results indicated an effect in favour of
combination treatment, compared with psychological therapy
alone (OR 3.08, 95% CI 1.63 to 5.84) Analysis 3.12.
• At six to nine months follow-up, the effect is unclear (OR
0.60; 95% CI 0.35 to 1.02) Analysis 3.13.
• At 12 months, the effect remains unclear (OR 1.15; 95%
CI 0.66 to 2.00) Analysis 3.14.
3.15 to 3.17 Depressive symptoms: Clinician rated
The TADS 2004 trial (n = 218) was the only study to provide data
for this outcome.
• At post-intervention, there was evidence of an effect
favouring combination treatment in producing lower levels of
clinician rated depressive symptoms compared with
psychological therapy alone (MD -8.27, 95% CI -10.58 to -
5.96) Analysis 3.15.
• At six to nine months follow-up, the effect is in the same
direction, favouring combination treatment, however the effect
no longer reaches significance (MD -0.87, 95% CI -3.10 to
1.36) Analysis 3.16.
• At 12 months there remains a small effect favouring
combination treatment that does not reach significance (MD -
1.60, 95% CI -3.49 to 0.29) Analysis 3.17.
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3.18 to 3.20 Depression symptoms: Self rated
Self rated depression symptom scores were obtained for two trials
(Melvin 2006; TADS 2004) in this comparison (n = 265).
• At post-intervention, the effect of the two treatment
approaches on self rated depression scores is unclear (SMD -
0.28, 95% CI -1.41 to 0.84) Analysis 3.18. The direction of the
effect of the two trials included in the meta-analysis is opposite
(there was significant heterogeneity between the trials (I2 = 92%,
P = 0.0004)), with TADS 2004 favouring combination therapy
and Melvin 2006 favouring psychological therapy alone.
• At six to nine months follow-up, the effect remains unclear
with the direction of effect the opposite for each trial included in
the meta-analysis (SMD -0.16, 95% CI -0.63 to 0.31) Analysis
3.19.
• At 12 months follow-up only data from TADS 2004 was
available and the effect is unclear (MD -3.10, 95% CI -6.38 to
0.18) Analysis 3.20.
3.21 to 3.22 Functioning
Functioning data was only obtained from Melvin 2006.
• At post-intervention, the effect of psychological therapy
alone compared with combination therapy is unclear (MD -
2.38, 95% CI -8.65 to 3.89) Analysis 3.21.
• At six to nine months, the effect of each intervention
approach is unclear (MD 0.43, 95% CI -7.04 to 7.90) Analysis
3.22.
• No data was available for 12 months follow-up.
Comparison 4: Combination therapy versus psychological
therapy plus placebo
All of the trials in this comparison were unique to those de-
scribed in the above comparisons in that they targeted comorbid
diagnoses, rather than depression in isolation. Additionally the
Bernstein 2000 trial contained participants with a diagnosis of
school refusal syndrome in addition to a comorbid diagnosis of
depression and anxiety.
We included four studies (n = 249) for this comparison (Bernstein
2000; Cornelius 2009; Deas 2000; Riggs 2007).
Remission from depressive disorder by clinical interview
No data were reported for this outcome measure.
4.1 Dropouts
All four studies provided data for dropouts at post-intervention.
• At post-intervention (n = 249) the effect on the dropout
rate for participants receiving a combination treatment
compared with a psychological therapy plus placebo treatment
was unclear (OR 0.98, 95% CI 0.42 to 2.28) Analysis 4.1.
• No data were available for comparisons at six to nine
months or 12 months follow-up.
Suicide-related SAEs
Riggs 2007 reports that there were no serious suicide attempts
or completed suicides during the trial; however, five participants
were seen in the emergency room for ’worsening suicidality’; four
participants were in the medication group and one was in the
placebo group.
4.2 Suicide-related behaviours
One trial (Riggs 2007) containing 126 participants reported data
based on question 13 of the CDRS-R about suicidal ideation.
• At post-intervention, the effect of combination treatment
compared with psychological therapy plus placebo was unclear
(MD -0.06, 95% CI -0.36 to 0.24) Analysis 4.2.
4.3 and 4.4 Remission from depressive disorder by cut-off
Two studies (Bernstein 2000; Riggs 2007) containing 173 partic-
ipants provided data for this outcome.
• At post-intervention, there was evidence of an effect
favouring combination treatment compared with psychological
therapy plus placebo (OR 2.15, 95% CI 1.15 to 4.02) Analysis
4.3.
• No data were reported for the six to nine months follow-up.
• At 12 months follow-up, data from Riggs 2007 were
available. The effect of the two treatment approaches was unclear
(OR 1.20, 95% CI 0.29 to 5.02) Analysis 4.4.
4.5 Depressive symptoms: Clinician rated
Data concerning clinician rated depressive symptoms were avail-
able from three studies (Bernstein 2000; Cornelius 2009; Riggs
2007) containing a total of 239 participants.
• At post-intervention, there was evidence that combination
therapy, resulted in significantly lower levels of clinician rated
depressive symptoms compared with psychological therapy plus
placebo (SMD -0.52, 95% CI -0.78 to -0.26) Analysis 4.5.
• No data were available for six to nine months or 12 months
follow-up.
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4.6 Depressive symptoms: Self rated
Three studies (Bernstein 2000; Cornelius 2009; Deas 2000) con-
taining a total of 123 participants provided data for self reported
depressive symptoms.
• At post-intervention, although self reported depressive
symptoms were lower in the combination condition, this did not
reach significance (SMD -0.34, 95% CI -0.70 to 0.02) Analysis
4.6.
• There were no data available for six to nine months or 12
months follow-up.
Functioning
There were no suitable data for this outcome.
While included as objectives, we did not have the data and so we
were unable to explore subgroup analyses of the potential modify-
ing effects of age and severity of depression on the results reported
above.
D I S C U S S I O N
Summary of main results
We have compared psychological therapy alone, antidepressant
medication alone, and a combination of the two, for the treatment
of depression in children and adolescents. We included 10 studies
in our review, with participants aged 8 to 19 years.
We could not draw clear conclusions from our analysis; we could
pool few data for meta-analysis because of the variety of interven-
tions, there were small numbers of studies in each comparison,
and data were conflicting at times.
Psychological therapy versus antidepressant
medication
The effect of antidepressants on remission rates (as defined by clin-
ical interview) was unclear compared with psychological interven-
tion. This is based on two studies using ITT data, and assumes
that those who dropped out during treatment did not achieve re-
mission (Melvin 2006; TADS 2004). Using OC data, there was a
small effect in favour of antidepressants because dropouts (who are
assumed not to have achieved remission in the medication group)
are not counted in the analysis. It cannot be assumed, however
that those who dropped out did not achieve remission, making the
results unclear. It should also be noted that this effect was driven by
the positive findings in the TADS 2004 study, but these were not
replicated by Melvin 2006. Nor is this finding supported by the
analysis using a cut-off on continuous measures to define remis-
sion. There was also no evidence of superiority of medication over
psychological therapy in the longer-term (Melvin 2006; TADS
2004). Significantly fewer instances of suicidal ideation were re-
ported in participants receiving psychological therapy compared
with medication post-intervention, and at three to six months fol-
low-up. Psychological therapy may be associated with less suicidal
ideation, however additional data are needed to substantiate this
claim.
The differences in short-term findings between the two studies
may be related to the use of different antidepressant medications
(Melvin 2006 used sertraline and TADS 2004 used fluoxetine).
Meta-analyses ( Whittington 2004) have asserted fluoxetine as the
more effective SSRI for reducing depressive symptoms in children
and adolescents. From the TADS 2004 study, it appears that flu-
oxetine may lead to a faster reduction in symptoms; however, it
appears no more beneficial than psychological therapy over time.
Sertraline was no more effective than psychological therapy. Ac-
ceptability of treatment, measured by dropout rate, did not dif-
fer between medication, and psychological therapy approaches.
Again, the finding that medication may lead to faster reduction in
symptoms should be interpreted with caution, given the inconsis-
tent results between TADS 2004 andMelvin 2006, and the diver-
sity in the direction of results across various outcome measures.
Combination therapy versus either psychologival
therapy or antidepressant medication alone
Given the above findings, a combination of treatment approaches
could be expected to provide both a faster treatment response
and potential protection against suicidality, and thus be superior
to medication or psychological intervention alone. We did not
find compelling data to support this view. The results differed by
outcome measure.
Combination therapy versus antidepressant
medication
• The TADS 2004 study did show that combination therapy
was superior to medication alone, immediately after intervention,
but this was only a significant effect for remission using a cut-off
score on a rating scale, and did not persist at follow-up.
• When a clinical interview was used to define remission,
while the effects favoured combination therapy up to six to nine
months follow-up, the effect did not reach significance (Clarke
2005; Melvin 2006; TADS 2004), and there were differences in
the direction of effect for each of the studies included (possibly
due to the different medications used in each trial), making the
effects of different intervention strategies on remission unclear.
Again, it should be noted that two of these trials reported this
outcome using observed case data (Melvin 2006; TADS 2004).
• In contrast, the ADAPT 2007 study favoured medication
alone. The collaborative context in which medication was
20Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
delivered in the ADAPT 2007 study may have influenced this
result. Participants receiving medication in this study did so
within a well co-ordinated case management approach.
• The effect of the different intervention approaches on
clinician rated depression symptoms were unclear. There were
some differences between groups on self rated depression, with
large variability within the data; the ADAPT 2007 and Clarke
2005 trials favoured medication alone at post-treatment, whereas
Melvin 2006 and TADS 2004 favoured combination therapy.
• At 12 months follow-up, meta-analysis based on two trials
(Clarke 2005; TADS 2004) favoured combination therapy,
resulting in significantly lower self reported depressive symptoms
in the longer-term.
• In one study that measured this outcome (TADS 2004),
rates of suicidal ideation at 12 months showed that combination
therapy may provide some protective benefits against suicidal
behaviour over time. Note that these differences were not
apparent immediately after intervention. The effects of the
treatment strategies were unclear on continuous measures of
suicidal ideation.
Combination therapy versus psychological therapy
• Based on two trials (Melvin 2006; TADS 2004), the effect
of the two intervention approaches to increase remission rates
(by clinical interview), was unclear. It should be noted that the
direction of effect in these trials differed and may be due to the
use of different SSRI compounds (fluoxetine in TADS 2004 and
sertraline in Melvin 2006), and again data were based on
observed cases only.
• The TADS 2004 trial was the only study to provide data for
remission based on a cut-off score, clinician rated depressive
symptoms and self rated depressive symptoms. At post-
intervention, there were significantly higher remission rates in
those receiving combination therapy; however, this benefit
appeared to be short-lived. .
• While not significant there was some evidence of a small
effect of combination therapy on clinician rated depressive
symptoms from TADS 2004.
• The effects on self reported depressive symptoms were
unclear with the direction of the effect differing for trials.
• There was no difference in rates of suicidal behaviours or in
suicidal ideation.
Combination therapy versus psychological therapy
plus placebo
These trials all included participants with a comorbid diagnosis of
either anxiety or addiction.
• Remission rates as defined by a cut-off score, were higher in
those receiving combination therapy at post-intervention only.
• Clinician rated depressive symptoms were lower at post-
intervention in those who received combination therapy
compared with psychological therapy plus placebo, based on
three trials (Bernstein 2000; Cornelius 2009; Riggs 2007).
• Although the effect was not as strong for self reported
depressive symptoms, results from all three trials favoured
combination therapy in general.
• There was no evidence of effect on suicide-related
outcomes.
Overall, these trials suggest that medication is exerting a small ef-
fect on depression, over and above that of a placebo pill, in the
short-term. This experimental design is interesting and method-
ologically robust.
As can be seen, there is limited evidence about the effects of differ-
ent treatment approaches. In the acute phase of treatment, medi-
cation may ensure a faster treatment response; however, the bene-
fit of medication over psychotherapy or a combination approach
does not appear to be maintained over time. The limited evidence
in this review suggests that psychological interventions may have
the potential to provide some protection against suicidal ideation
in the long-term, and may also result in effectiveness similar to
other treatment approaches in the long-term. These tentative con-
clusions should be interpreted with caution given the considerable
heterogeneity between trials, the variety of ways in which remis-
sion is defined across studies, and the inconsistent results across
other outcome measures.
Recent guidelines for the treatment of depression in adolescents
and young adults in Australia recommend psychotherapy as a first
line treatment in this population. Only when symptoms are se-
vere, should pharmacological approaches be considered, and then
only in combination with ongoing psychotherapy (McDermott
2010). These recommendations are consistent with a number of
guidelines produced internationally. The results of this review,
while not contradicting these recommendations, introduce some
uncertainty and highlight the need for more evidence to inform
the treatment of youth depression. In the absence of conclusive
evidence, guideline developers have to take into account a number
of factors, including the need to guide clinicians in their approach
to treatment.
Overall completeness and applicability of
evidence
With few trials available in each comparison and the availability
of data limited, it is difficult to draw conclusions at present about
the most effective course of treatment for young people with de-
pression.
Many of the significant outcomes derived from the meta-analyses
were driven by data from the TADS 2004 study. Although this
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trial is large and the design robust, its generalisability is limited
because a significant proportion of participants were recruited for
the study through advertisements and may not reflect those young
people seen in clinical practice.
Although all studies in the review contained participants with a
formal diagnosis of depression on a standardised and validated
scale according to DSM-III or DSM-IV criteria, there was consid-
erable variability in the study populations. For example, anxiety
disorders were comorbid in 50% of the studies (ADAPT 2007;
Bernstein 2000;Melvin 2006; TADS 2004; TASA 2009) and alco-
hol/substance use comorbid in two trials (Deas 2000; Riggs 2007).
Furthermore, in one trial all participants were formally diagnosed
with an anxiety disorder and school refusal syndrome (Bernstein
2000). While inclusion of these trials widens the diversity of the
sample in terms of clinical presentation, it should be noted that in
clinical practice, clients who present to services may be even more
complex in their presentation. Comorbid diagnoses are common
within the adolescent population, and the severity of depression
in participants is also varied. The ADAPT 2007 trial also required
that a young person had failed to respond to a trial of psychoso-
cial intervention in order to meet entry criteria. This subsample
of participants has been described as having “persistent ....depres-
sion” (Harrington 2002), and thus in essence may respond bet-
ter to a different class of treatment as a function of depression
persistence. The difference in study population between ADAPT
2007 (conducted in a clinical population), and TADS 2004 (with
high recruitment via advertising,) may limit the appropriateness
of performing meta-analysis on these two populations together.
There was also considerable variation in the type of medication
used in the trials. The majority used SSRIs, including fluoxetine,
venlafaxine and sertraline, with a couple of trials using a variety
of SSRIs and one trial using a TCA. Meta-analyses ( Whittington
2004) found that fluoxetine was the only SSRI to demonstrate
reliable efficacy in reducing depressive symptoms in children and
adolescents, and TCAs have no evidence of efficacy (Hazell 2002).
Combining studies with medications that have varying efficacy
limits the conclusions that can be drawn from this data set.
Many of the trials reported on adverse effects, and suicide-related
behaviours were also included within that battery of outcomes.
However, there was considerable variability in the way in which
these data were collected or reported, and it was challenging to
extract appropriate and homogenous data suitable for meta-anal-
ysis. It is important to report data concerning suicidality across
all treatment approaches in a consistent way so that meaningful
comparisons can be made. Brent 2009 found rates of suicidal and
non-suicidal self injury were higher in young people who were
systematically monitored for such outcomes. This highlights the
importance of collecting suicide-related measures systematically.
Although there were data on follow-up to 12 months the diversity
in trial design meant that few data could be aggregated.
We were unable to explore the potential modifying effects of age
and severity of depression on the results because this type of data
was also unavailable.
A strength of our review is that we used remission from disorder,
rather than response to treatment because it is a more stringent
measure and one that is more closely related to the goals of most
people seeking treatment.
Quality of the evidence
We included large scale RCTs such as TADS 2004 (n = 439) and
ADAPT 2007 (n = 208) in this review.
In general, the reporting of the conduct of trials allowed adequate
evaluation of the risk of bias. Around 50% of trials had adequate
sequence generation and allocation concealment. In the majority
of trials, outcome assessors were blind to intervention, reducing
the chance of experimenter bias. However, as is the nature with
administering psychological interventions, many participants in
the research trials would have been aware that they were receiving
a psychological intervention, which raises the potential for bias in
itself. ITT analysis was routinely used in the trials to account for
missing data and reported as such. However, for the primary out-
come of ’remission by clinical interview’ two trials, fromwhich the
majority of data were derived, report this on the basis of observed
case data only. It is unclear what the impact of missing participants
is on the outcome in this case.
There are also potential biases that arise from the design of studies.
Clarke 2005 allowed uncontrolled medication (any SSRI of any
dose) within the medication arm. A study of comparable design,
ADAPT2007, containedmuch stricter guidelines aroundmedica-
tion management during the experimental period. Furthermore,
participants in the medication only group were also administered
medication within the context of ongoing clinical care, during
which time there was some limited focus on recent family and peer
conflicts that could constitute more intensive case management
when compared with Clarke 2005.
Potential biases in the review process
The review authors wrote to trialists in order to obtain data relat-
ing to the outcomes specific to this review, and sought to locate all
published and unpublished trials testing the effect of a psycholog-
ical therapy or medication against a combination of the two. We
obtained some data from some trialists, and we have noted this
where applicable. However, not all authors were able to provide
data for our outcomes of interest.
Agreements and disagreements with other
studies or reviews
Two recent meta-analyses investigating the efficacy of combined
treatment with cognitive behavioural therapy (CBT) in adoles-
cent depression concluded that adding CBT to antidepressants re-
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sulted in little additional benefit over and above medication alone
(Dubrika 2010; Hetrick 2011). The reviews differed from ours
in two ways, only trials which tested new generation SSRIs were
included, and trials with ’treatment resistant’ participants were in-
cluded. Authors of these reviews cautioned against making firm
conclusions given the limitations of the data. It should be noted
that both reviews included the ADAPT 2007 trial. As highlighted
above, the context within which participants received medication
alone (compared to combination treatment) in this trial was col-
laborative, and co-ordinated in nature, meaning that any potential
benefits of adjunctive CBT tomedication could have beenmasked
by this procedure.
A number of recent reviews have concluded that SSRIs are associ-
ated with an increase in suicidal behaviour in children and adoles-
cents (Dubicka 2006; Hammad 2006; Hetrick 2007). There are
limited data from this review that suggest that suicidal ideation
is more common in participants treated with medication in iso-
lation, compared with psychological therapy at post-intervention
and three- to six-month follow-up, or a combination of the two
at 36-week follow-up. The data also suggest that suicidal ideation
decreased less with medication only. It is possible that psychologi-
cal therapymay exert a protective effect against suicidal behaviours
when combined with medication.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is little evidence about the benefits and risks of various ap-
proaches to treating child and adolescent depression, with differ-
ences in type of participants and the treatment regimens in studies
published to date.
It was not possible in this review to draw robust conclusions, nor
to establish which intervention strategy was most effective.
Implications for research
Further research is needed in which: i) remission is used as a main
outcome measure, in order to assess the effectiveness of an in-
tervention in treating depression in children and adolescents; ii)
measures of suicidal-related behaviours are measured robustly and
consistently; iii) combination interventions are evaluated in young
people who have first failed to respond to a first line psychological
therapy for depression such as CBT or IPT. Given the dominance
of the combination approach to treatment, it is unlikely, although
it may still be useful to investigate the efficacy of psychothera-
pies against medication. There is a need for studies in popula-
tions that are more representative of the clinical populations tak-
ing into account the severity of depression at presentation. One
of the practical difficulties in clinical practice is accessing CBT or
IPT. Techonology has enabled a variety of creative and innovative
methods of delivering psychological interventions (e.g. telephone,
Internet; Richardson 2010), and while this isn’t yet reflected in
the literature in terms of high quality RCTs, studies testing these
innovations in delivery methods would be worthwhile.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ADAPT 2007
Methods Duration: 12 weeks
Follow-up assessment points: Post-intervention, 28 weeks
Funded by: NHS Health Technology Assessment (HTA) Programme, Central Manch-
ester and Manchester Children’s University Hospitals
Participants N = 208
Adolescents only (11 to 17 years)
Depression diagnoses included:DSM-IV; criteria formajor or probablemajor depression
(four symptoms with psychosocial impairment). Participants also had to obtain a score
of 7 or more on the Health of the Nation Outcome scales for children and adolescents
(HoNOSCA; Gowers 1999)
Baseline risk of suicide: Measured using the suicidality items from the Kiddie Schedule
for Affective Disorders and Schizophrenia Present and Lifetime Version (K-SADS-PL;
Kaufman 1997). Patients with active suicidal intent were included in the study
Baseline Fluoxetine + CBT n = 105 (%) Fluoxetine n = 103 (%)
Thoughts 50 (47.6) 48 (46.6)
Ideation 40 (38.1) 44 (42.7)
Acts 13 (12.4) 21 (20.4)
Medical lethality 3 (2.9) 4 (3.9)
Self harm 30 (28.6) 23 (22.3)
Baseline severity of depression: Children’s Depression Rating Scale-Revised (CDRS-R;
Poznanski 1996). Mean t-score (SD): Fluoxetine + CBT = 75.1 (6.7) Fluoxetine = 75.
3 (6.7)
Comorbidity included:
Comorbidity Fluoxetine + CBT (n = 105) Fluoxetine
(n = 103)
Social Phobia 43 49
Obsessive compulsive disorder 42 37
Post-traumatic stress disorder 42 36
Agorophobia 36 29
Separation anxiety disorder 31 28
Specific phobia 25 22
Conduct disorder 18 17
Panic disorder 21 14
Oppositional defiance disorder 17 13
Generalised anxiety disorder 19 13
Panic disorder (with agoraphobia) 20 13
ADHD 5 6
Bulemia Nervosa 8 4
Alcohol abuse 1 4
Transient tic disorder 2 3
Tourettes syndrome 2 2
Alcohol dependence 1 2
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Age: Range = 11 to 17 years
Fluoxetine + CBT (median) = 14
Fluoxetine (median) = 14
Sex (M:F):
Total: 54:154
Fluoxetine + CBT = 26:79
Fluoxetine = 28:75
Setting: Outpatient setting
Excluded psychiatric diagnoses: Schizophrenia or bipolar disorder; global learning dis-




Name: CBT with core interventions including engagement and goal setting, emotional
recognition, self monitoring, self reinforcement and activity scheduling, challenging neg-
ative thinking and cognitive restructuring, social problem-solving and communication
skills
# sessions/length: 19 sessions over 28 weeks. (1 session per week for 12 weeks, 1 session
per fortnight for 12 weeks, 1 final session at 28 weeks)
Manualised (Y/N): Yes
Individual or group: Individual
Parent involvement: Encouraged at the end of each session by therapist
Fidelity check: Yes. Audiotapes of the session were rated with a modified version of the
cognitive therapy scale (Vallis 1986) Inter-rater reliability k = 0.8
Delivered by: 4 Psychiatrists who either had previous CBT training or attended a 3-day
training course on CBT for depression, and 10 CBT therapists (mostly Psychologists)
Name (class & type): SSRI (Fluoxetine). However, 26 participants were taking a different
SSRIwhen admitted to the trial; 3 switched to fluoxetine and 11 changed fromfluoxetine
to another SSRI
Dose (mg/day)/length: 10 mg daily for 1 week, increasing to 20 mg for 5 weeks. If no
response, increase considered to 40 mg on alternate days for one week followed by 5
weeks of 40 mg. Option to increase dose to 60 mg on alternate days for 1 week followed
by 60 mg daily for 5 weeks if participant did not respond by 12 weeks. Overall, there
was a mean dose of 30 mg for both groups, and 2 patients received 60 mg
Delivered by: psychiatrists in the context of ongoing clinical care. The content of contact
was an explanation of depression and attention to recent family or peer group conflicts.
Liaison with schools and other agencies undertaken when appropriate. Participants of-
fered 9 outpatient sessions of usual care over 28 weeks, with the option of more if needed
Medication Only
N = 103
Medication details as above Y/N: Yes
Outcomes Clinician reported
The Children’s Depression Rating Scale-Revised (CDRS-R; Poznanski 1996)
Children’s Global Assessment Scale (C-GAS; Shaffer 1983)
Suicidality items from the Kiddie Schedule for Affective Disorders and Schizophrenia
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ADAPT 2007 (Continued)
Present and Lifetime Version (K-SADS-PL; Kaufman 1997)
Self reported
The Mood and Feelings Questionnaire (MFQ; Wood 1995)
Parent reported
The Clinical Global Impression Improvement Scale (CGI-I; Guy 1976)
Additional Measures
The Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA;
Gowers 1999)
The Clinical Global Impression Improvement Scale (CGI-I; Guy 1976)
Notes Dropouts during treatment to any or at least 1 adverse reaction: 1 participant experienced
a fit possibly related to SSRI and 1 had an allergic reaction (possibly secondary to
medication)
Suicide-related outcome as an adverse event of treatment: 4 required admission for
suicidality or self harm and were withdrawn from the study
Authors only report median age
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Participants were randomised to SSRI
alone or SSRI plus CBT by an equal allo-
cation ratio using stochastic minimisation
balancing for severity (Childrens Global
Assessment Scale <40), centre, sex, concur-
rent comorbidity disorder, and age”
pg. 2/8 (Under heading Assignment)
Allocation concealment (selection bias) Low risk “Research staff from the clinical sites
enrolled patients, and an independent
telephone randomisation centre allocated
treatment”
pg. 2 /8 (Under heading Assignment)
Blinding (performance bias and detection
bias)
Assessors
Low risk “...research assistants blind to treatment
assignment assessed outcome”
pg. 4/8 (Under heading Outcomes)
Blinding (performance bias and detection
bias)
Participants
High risk No placebo or control psychotherapy was
used. As such, participants would be aware
that themedicationwas active and the ther-
apy was CBT
Incomplete outcome data (attrition bias) Low risk ITT analysis: “Analysis was by intention to
treat subject to the availability of the data”
pg. 4/8 (Under heading Statistical Analysis)
Number randomised:
Fluoxetine + CBT: 105 Fluoxetine:
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ADAPT 2007 (Continued)
103 Total: 208
Number of dropouts during intervention:
Fluoxetine + CBT: 11 Fluoxetine:6
Total: 17
Number dropouts in follow-up:
Fluoxetine + CBT: 7 Fluoxetine: 7
Total: 14
Number analysed post-intervention:
Fluoxetine + CBT: 105 Fluoxetine:
103 Total: 208
Number analysed follow-up 1:
Fluoxetine + CBT: 105 Fluoxetine:
103 Total: 208
Reasons for dropout in each group:
12 patients were formally withdrawn from
the study for the following reasons: 4 re-
quired admission to hospital for suicidality
or self harm, 5 failed to improve, 1 had a fit,
1 had an allergic reaction, 1 was prescribed
paroxetine by a GP
18 families withdrew participants from the
study: 6 were improving and did not want
further treatment, 5 did not want more
treatment, 2 wanted CBT, 2 did not want
CBT, 1 wanted a female therapist, 1 was
getting worse, 1 moved
Selective reporting (reporting bias) Unclear risk Authors reported data for all outcomes
specified in their methods. Do not have ac-
cess to trial protocol
Other bias Low risk
Bernstein 2000
Methods Duration: 8 weeks
Follow-up assessment points: Post-intervention, 12 months
Funded by: National Institute of Mental Health (NIMH)
Participants N = 63
Adolescent only (12 to 18 years)
Depression diagnoses included: DSM-III-R Major Depressive Disorder (MDD). Partic-
ipants also had to obtain a score of 35 or more on the CDRS-R (Poznanski 1996)
Baseline risk of suicide: Not measured
Baseline severity of depression: Chidren’s Depression Rating Scale (CDRS-R; Poznanski
1985). Mean score (SD):
Imipramine + CBT = 46.8 (9.5)
Placebo + CBT = 52.5 (10.8)
Comorbidity included: All 63 subjects met criteria for at least 1 anxiety disorder based
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Bernstein 2000 (Continued)
on either adolescent or parental interviews
Age mean (SD):
Total = 13.9 (3.6)
Sex (M:F): 25:38
Setting: Unclear. Likely an outpatient setting based on information regardingmedication
monitoring throughout the trial
Excluded psychiatric diagnoses: ADHD, conduct disorder, bipolar disorder, eating dis-
order, alcohol or drug abuse on the Diagnostic Interview for Children and Adolescents-
Revised-Adolescent Version (DICA-R-A) or Parent Version (DICA-R-P; Reich 1990),
or both, mental retardation by history, bipolar affective disorder in first degree relative
Country: USA
Interventions Combination (Imipramine + CBT)
N = 31
Name: CBT. Based on school refusal treatment by Last 1998. Included the identifica-
tion of negative thoughts surrounding school attendance and teaching adaptive coping
strategies
# sessions/length: 8 (45 to 60 minutes) sessions over 8 weeks
Manualised (Y/N): Yes
Individual or group: Individual
Parent involvement: Yes. Parents joined each session for 10 to 15 minutes at the end
Fidelity check: No formal check. Weekly discussions with all therapists and principal
investigators, and a fortnightly telephone consultation with an expert on CBT for school
refusal
Delivered by: 3 therapists (1 behaviorally trained Clinical Psychologist, 1 Doctoral level
therapist and 1 Masters level therapist)
Name (class & type): TCA (Imipramine)
Dose (mg/day)/length: Dose based on body weight. A gradual increase every 3 to 5 days
to 3 mg/kg per day by the end of week 2 Mean dose at week 3 was 184.6mg + 33.3
Delivered how: Weekly appointments monitoring side effects, and compliance were
undertakenwith a psychiatrist. Blood imipramine levels weremonitored at 3 and 8weeks
Combination (Placebo medication + CBT)
N = 32
Details as above (Y/N): Yes
Outcomes Clinician reported
Children’s Depression Rating Scale-Revised (CDRS-R; Poznanski 1985) with a score of
≤ 35
Children’s Depression Rating Scale-Revised (CDRS-R; Poznanski 1985)
Self reported
The Beck Depression Inventory (BDI; Beck 1979)
Additional Measures
Anxiety Rating for Children-Revised (ARC-R; Bernstein 1996)
The Revised Children’s Manifest Anxiety Scale (RCMAS; Reynolds 1978)
Weekly school attendance rates
Notes Dropouts during treatment to any or at least 1 adverse reaction: 1 participant developed
manic symptoms and 1 developed psychiatric symptoms and required hospitalisation
Suicide-related outcome as an adverse event of treatment: No
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Bernstein 2000 (Continued)
Denominator and numerator for remission rates calculated from percentages reported
in the publication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “Random assignment to treatment was
blocked on gender and whether subjects
had a school vacation that lasted 5 or more
days during the 8 week treatment period”.
(Under heading Procedure)
Allocation concealment (selection bias) Unclear risk No information contained in paper to
make a judgement
Blinding (performance bias and detection
bias)
Assessors
Low risk “All project personnel...were blind to med-
ication assignment”. (Under heading Pro-
cedure)
Blinding (performance bias and detection
bias)
Participants
Low risk ”...imipramine pills andmatching placebo“
“To preserve the blind, increases and de-
creases were also suggested for randomly se-
lected patients on placebo”. (Under head-
ing Medication Management)
Incomplete outcome data (attrition bias) Low risk ITT analysis: “All randomized subjects
were included in analyses based on intent
to treat”. (Under heading Statistical Anal-
yses)
Number randomised:
Imipramine + CBT: 31 Placebo + CBT:
32 Total: 63
Number of dropouts during intervention
Imipramine + CBT: 7 Placebo + CBT:
9 Total: 16
Number analysed post-intervention:
Imipramine + CBT: 31 Placebo + CBT:
32 Total: 63
Reasons for dropout in each group: 1
missed 22 does of medication, 1 missed 2
therapy appointments, 1 developed manic
symptoms on study medication, 1 required
hospitalisation for psychiatric symptoms,
and 12 declined further participation
Selective reporting (reporting bias) Unclear risk Authors report data for all outcomes post-
intervention. Do not have access to trial
protocol
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Bernstein 2000 (Continued)
Other bias High risk Authors note that placebo group signifi-
cantly more symptomatic at baseline com-
pared with imipramine group despite ran-
domisation
Clarke 2005
Methods Duration: 6 weeks
Follow-up assessment points: Post-intervention, 12, 26 and 52 weeks
Funded by: The Agency for Healthcare Research and Quality and the GarfieldMemorial
Fund
Participants N = 152
Adolescent only (12 to 18 years)
Depression diagnoses included: DSM-IV episode of major depression
Baseline risk of suicide: 73.7% (112/152) of participants reported significant levels of
suicidal behaviour; assessment tool not explicitly referenced
Baseline severity of depression: Centre for Epidemiological Studies - Depression Scale
(CES-D; Radloff 1977):
TAU + CBT = 35.4 (11.8)
TAU = 33.7 (9.3)
Comorbidity included: Not reported
Age mean (SD):
Total = 15.30 (1.61)
TAU + CBT = 15.29 (1.62)
TAU = 15.32 (1.60)
Sex (M:F): 34:118
TAU + CBT = 17:60
TAU = 17:58
Setting: Primary care health maintenance organization (HMO)
Excludedpsychiatric diagnoses: Schizophrenia or a significant developmental/intellectual
disability
Country: USA
Interventions TAU (SSRI) + CBT
N = 77
Name: CBT employing cognitive restructuring, or behavioural training, or both. Par-
ticipants able to choose which type to try first. After completion of first module (2 to 5
sessions), therapist and youth reviewed recovery and decided whether to proceed with
the second module (sessions 6 to 9), focusing on skills training
# sessions/length: Between 0 and 9, mean 5.3 sessions. Each session 1 hour. Weekly in
frequency
Manualised (Y/N): No information
Individual or group: Individual
Parent involvement: Clinicians organised separate parent meetings, however “parents’
attendance was ”sparse“
Fidelity check: Yes. All sessions audio taped. 57 sessions selected at random and rated by
a senior supervisor. 87.2% adherence to protocol
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Clarke 2005 (Continued)
Delivered by: Masters level Psychologists
Name (class & type): SSRI (varied). All trial participants were able to receive any medi-
cations provided by either the HMO or outside providers
Dose (mg/day)/length: Varied
Delivered by: No information
TAU (SSRI)
N = 75
Details as above (Y/N): Yes
Outcomes Clinician reported
Mood disorders module of the Schedule for Affective Disorders and Schizophrenia for
School-age Children-Present and Lifetime version (K-SADS-PL; Kaufman 1997) and
the Longitudinal Interview Follow-Up Evaluation (Keller 1982).
This was used to define remission i.e. those who had did not have a continuing or new
mood disorder since the last interview according to the K-SADS-PL). It was unclear if
DSM-IV or ICD time criteria were employed
Centre for Epidemiological Studies-Depression Scale (CES-D; Radloff 1977), cut-off of
≤ 15
Children’s Global Adjustment Scale (C-GAS; Shaffer 1983)
Self reported
Centre for Epidemiological Studies-Depression Scale (CES-D; Radloff 1977)
Parent reported
The Child Behaviour Checklist (CBCL; Achenbach 1978)
Additional Measures
Hamilton Rating Scale for Depression (HAM-D; Hamilton 1960)
Youth Self Report (YSR; Achenbach 1991)
Internalising and Externalising subscales and an extracted depression subscale created to
match DSM criteria for major depression (Clarke 1992)
Social Adjustment Scale Self Report for Youth (Weissman 1980)
Short Form-12 (Ware 1998)
Notes Authors do not report reasons for dropout
Dropouts during treatment to any or at least 1 adverse reaction: Not reported
Suicide-related outcome as an adverse event of treatment: Not reported
Numbers who reached remission by interview were calculated by review authors using
percentages based on depressive episodes (Table 3). Data from Table 3 were based on
observed cases not ITT following advice from statistician
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Youths were randomized using a blocked
procedure to minimize study arm imbal-
ance”. pg. 889
Allocation concealment (selection bias) Unclear risk No information contained in paper to
make a judgement
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Clarke 2005 (Continued)
Blinding (performance bias and detection
bias)
Assessors
Low risk ”Blinded interviewers assessed each ado-
lescent and a participating parent by tele-
phone at baseline and at 6, 12, 26 and 52
weeks post-randomization”. pg. 890
Blinding (performance bias and detection
bias)
Participants
High risk No placebo or therapy control arm. As
such, participants were aware if they were
receiving CBT in the trial or not
Incomplete outcome data (attrition bias) Unclear risk ITT analysis: ”...all subjects were consid-
ered part of the study from the point of
randomisation (an intent-to-treat design)“
pg.890
“We examined continuous depression and
functioning outcome measures using ran-
dom effect regression analysis”. pg. 892
Number randomised:




TAU + CBT: 67 (10) TAU: 65
(10) Total: 132 (20)
Number completing follow-up 12 weeks:
TAU + CBT: 61 (16) TAU: 61
(14) Total: 122 (30)
Number completing follow-up 26 weeks:
TAU + CBT: 65 (12) TAU: 62
(13) Total: 127 (25)
Number completing follow-up 52 weeks:
TAU + CBT: 56 (21) TAU: 58
(17) Total: 114 (38)
*Data obtained from Fig 1. Summary of
study procedures. Number analysed not
clearly stated in paper
Reasons for dropout in each group: Not
reported
Selective reporting (reporting bias) Unclear risk Remission rates only reported at 52 weeks.
Do not have access to trial protocol
Other bias High risk Authors note that telephone administra-
tion of self report measures may have cre-
ated bias
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Cornelius 2009
Methods Duration: 12 weeks
Follow-up assessment points: Post-intervention (12 weeks)
Funded by: National Institute on Alcohol Abuse and Alcoholism
Participants N = 50
Adolescent only (15 to 20 years)
Depression diagnoses included: DSM-IV diagnosis of major depressive disorder (MDD)
Baseline risk of suicide: Not measured and suicidality not stated as an exclusion criteria
Baseline severity of depression: Hamilton Rating Scale for Depression (HAM-D;
Hamilton 1960) Mean (SD):
CBT + fluoxetine = 16.88 (7.09)
CBT + placebo = 22.88 (8.79)
Comorbidity included: All participants were required to have a DSM-IV diagnosis of
an alcohol use disorder (AUD) confirmed using the Substance Use Disorders Section of
the Structured Clinical Interview for the DSM (SCID)
Age mean: Not reported
Sex (M:F):
Total = 28:22
CBT + fluoxetine = 12:12
CBT + placebo = 16:10
Setting: Outpatient?
Psychiatric diagnoses excluded: DSM-IV diagnosis of bipolar disorder, schizoaffective
disorder, or schizophrenia, persons with and substance abuse or dependence other than
nicotine dependence or cannabis use and dependence, persons with a history of intra-
venous drug use, persons who had received antipsychotic or antidepressant medication
within 1 month prior to baseline assessment also excluded
Country: USA
Interventions Combination: Psychotherapy + Medication
N = 24
Name (description): CBT for depressive disorder and the treatment of alcohol use dis-
order combined with Motivation Enhancement Therapy (MET) for the treatment of
alcohol use disorder
# sessions/length: 9 sessions over 12 weeks
Manualised (Y/N): Yes
Individual or group: Not reported
Parent involvement: Not reported
Fidelity check: No fidelity check reported
Delivered by: Not reported
Medication
Name (class & type): SSRI; fluoxetine
Dose (mg/day)/length: initiated at 10 mg, increased to 20 mg after week 2 until the end
of the study, as 20 mg was target dose of the study
Delivered how: Study physicians prescribed all medication
Combination: Psychotherapy + Placebo
N = 26
Delivered how: Pill placebo delivered in the same context as above
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Outcomes Clinician reported
Hamilton Rating Scale for Depression (HAM-D; Hamilton 1960)
Self reported
Beck Depression Inventory (BDI; Beck 1988)
Additional Measures
Drinking behaviour measured using the Timeline Follow-back Method (TLFB; Sobell
1988)
Notes Dropouts during treatment to any or at least 1 adverse reaction: 0
Suicide-related outcome as an adverse event of treatment: 0
Suicidality was not measured with a formalised tool
3 dropouts during study from placebo group due to persistent depressive symptoms
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patient randomisation was conducted by
urn randomisation stratified by gender” pg.
906 (Treatment and assessment)
Allocation concealment (selection bias) Low risk “Active medication and matching placebo
were prepared by the research pharmacy”
pg. 906 (Treatment and assessment)
Blinding (performance bias and detection
bias)
Assessors
High risk “The study was conducted in a double
blind fashion, though one study physician
remained non-blinded in order to handle
any problems which may have arisen” pg.
906 (Assessment and treatment)
Blinding (performance bias and detection
bias)
Participants
Low risk ”...participants were randomly assigned to
receive fluoxetine or placebo administered
in identical-looking opaque capsules” pg.
906 (Assessment and treatment)
Incomplete outcome data (attrition bias) Unclear risk “Statistical analyses were completed on an
intent-to-treat study group” pg. 907 (Sta-
tistical Analyses)
Number randomised:
CBT + fluoxetine: 24 CBT + placebo: 26
Number dropped out during intervention:
CBT + fluoxetine: 0 CBT + placebo: 3
Number analysed post-intervention:
CBT + fluoxetine: 24 CBT + placebo: 26
Selective reporting (reporting bias) Unclear risk Do not have access to trial protocol
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Other bias Low risk Baseline imbalance of HAM-D and BDI
scores with fluoxetine group have signifi-
cantly lower baseline depression scores
Deas 2000
Methods Duration:12 weeks
Follow-up assessment points: Post-intervention
Funded by: National Institute of Alcohol and Alcoholism (NIAAA)
Participants N = 10
Adolescent only (15 to 18 years)
Depression diagnoses included: Not clearly stated. The Child Schedule for Affective
Disorders and Schizophrenia (K-SADS; Chambers 1985) was used to assess psychiatric
disorders
Baseline risk of suicide: Not measured
Baseline severity of depression:measured using theHamiltonRating Scale forDepression
(HAM-D; Hamilton 1960)
Sertraline + CBT = 20.40 (5.55)
Placebo + CBT = 20.80 (5.45)
Comorbidity included: All participants presented with an alcohol use disorder
Age mean (SD): Total = 16.6 (0.52)
Sertraline + CBT = 16.4 (0.55)
Placebo + CBT = 16.8 (0.45)
Sex (M:F): 8:2
Sertraline + CBT = 4:1
Placebo + CBT = 4:1
Setting: Outpatient




Name (description): CBT focusing on relapse prevention, coping skills, anger manage-
ment, modelling and role playing
# sessions/length: 12, average attendance was 8.2 sessions and 10.6 sessions for the
placebo and sertraline groups respectively
Manualised (Y/N): No
Individual or group: Group
Parent involvement: Not reported
Fidelity check: Not reported
Delivered by: A psychiatrist, on a weekly basis
Name (class & type): SSRI (Sertraline)
Dose (mg/day)/length: 25 mg/day, increased to 25 mg weekly, to a maximum dose of
100 mg in about 4 weeks
Delivered by: A psychiatrist monitored side effects, made medication adjustments, and
supplied participants with additional medication on a weekly basis
Combination (Placebo medication + CBT)
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Deas 2000 (Continued)
N = 5
Details as above (Y/N): Yes
Outcomes Self reported
Outcome 4: Hamilton Rating Scale for Depression (HAM-D; Hamilton 1960)
Additional Measures
The Time Line Follow Back (TLFB; Sobell 1988) assessed alcohol use
Notes Dropouts during treatment to any or at least 1 adverse reaction: No. Authors note that
all the side effects of sertraline were transient and did not lead to any dropouts
Suicide-related outcome as an adverse event of treatment: No
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Following the baseline assessments, sub-
jects were randomized using a computer-
generated randomisation table into sertra-
line or placebo groups” pg. 462
Allocation concealment (selection bias) Low risk All of the medication supplied by the study
pharmacist were identical in appearance“
pg. 462
Blinding (performance bias and detection
bias)
Assessors
Unclear risk “This study was a 12 week double blind,
placebo-controlled trial” pg. 462
Blinding (performance bias and detection
bias)
Participants
Low risk Participants in both arms were blind to
medication. Both received CBT
“This study was a 12 week double blind,
placebo-controlled trial” pg. 462
Incomplete outcome data (attrition bias) Unclear risk ITT analysis: All subjects randomised were
included in the final analysis. No infor-
mation is reported regarding imputation
method for missing data
Number randomised:
SSRI + CBT: 5 Placebo + CBT: 5
Total: 10
Number of dropouts during intervention:
*
SSRI + CBT: 2 Placebo + CBT: 0
Total: 2
Number analysed post-intervention:
SSRI + CBT: 5 Placebo + CBT:5
Total: 10
Treatment completion was defined a priori
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as 8 sessions
Selective reporting (reporting bias) Unclear risk All outcome data specified in methods was
reported. Do not have access to trial proto-
col
Other bias High risk Small study sample, and no follow-up
Mandoki 1997
Methods Duration: 6 weeks
Follow-up assessment points: Post-intervention
Funded by: Not specified
Participants N = 33
Child and adolescent (8 to 17 years)
Depression diagnoses included: DSM-IV Major Depression
Baseline risk of suicide: Participants who were acutely suicidal were excluded form the
study. No other specific suicide measurements were administered
Baseline severity of depression: Not reported
Comorbidity included: Not reported
Age mean (SD): Total based on completed participants: 12.7 (2.88)
Sex (M:F): 25:8
Setting: Outpatient
Excluded psychiatric diagnoses: Schizophrenia, mental retardation and Gilles de la
Tourette’s syndrome
Country: USA
Interventions Combination (SNRI + Psychotherapy)
N = 20
Name: Predominantly behavioural/cognitive in nature
# sessions/length: One weekly session over 6 weeks
Manualised (Y/N): Not reported
Individual or group: Individual sessions of 60 minutes (45 minutes plus 15 minutes
”collateral“)
Parent involvement: 15 minutes at the end of each session was ”collateral“ with parents
and participants
Fidelity check: Not reported
Delivered by: Masters level therapists, trained in the procedural aspects of the study
Name (class & type): SNRI (Venlafaxine)
Dose (mg/day)/length: Children (8 to 12 yrs) began at 12.5 mg q.d for 3 days, increasing
to 12.5 mg b.i.d for 3 days, and further increased to 12.5 mg t.i.d for the remainder of
the study. Adolescents (13-17yrs) began at 25mg q.d. for 3 days, increased to 25mg b.i.
d for 3 days and then 25mg t.i.d. for the remainder of the study
Delivered how: Weekly clinic supplied medication/placebo and monitored vital signs
and side effects
Combination (Placebo+Psychotherapy)
44Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mandoki 1997 (Continued)
N = 20
Details as above (Y/N): Yes
Outcomes Clinician reported
The Child Depression Rating Scale (CDRS; Poznanski 1979)
Self reported
Children’s Depression Inventory (CDI; Kovacs 1992)
Parent reported
The Child Behaviour Checklist (CBCL; Achenbach 1993)
Additional Measures
The Hamilton Rating Scale for Depression (Hamilton 1960)
Notes Age and gender calculated manually from Figure 1
Dropouts during treatment to any or at least 1 adverse reaction: One participant devel-
oped a manic episode, was hospitalised and subsequently put on lithium. Authors note
in discussion that ”There are specific side effects associated with venlafaxine treatment..
..However, these side effects were not severe enough to discontinue the medication“
Suicide-related outcome as an adverse event of treatment: None reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information contained in paper to
make a judgement
Allocation concealment (selection bias) Unclear risk As authors quote study as being ’double
blind’
Blinding (performance bias and detection
bias)
Assessors
Low risk ”After the 6-week treatment, the study
ended. The blind was broken...”. pg. 151
Under heading Procedures,Measurements,
and Medication Dose
Blinding (performance bias and detection
bias)
Participants
Low risk “The patients were randomly assigned, in
a double blind fashion, to either the ven-
lafaxine and psychotherapy or the placebo
and psychotherapy treatment group”. pg.
151 Under heading Procedures, Measure-
ments, and Medication Dose
Incomplete outcome data (attrition bias) High risk ITT analysis: No. “Figure 1 shows the age
and sex composition of the final sample on
which the statistical analysis was based”.
Manual calculation shows the analysis was
conducted only on participants completing
the trial. pg. 150 Under heading Subjects
Number randomised:
SNRI + Psychotherapy: 20 Placebo
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+ Psychotherapy: 20 Total: 40
Number of dropouts during intervention:
SNRI + Psychotherapy: 4 Placebo
+ Psychotherapy: 3 Total: 7
Number analysed post-intervention:
SNRI + Psychotherapy: 16 Placebo
+ Psychotherapy: 17 Total: 33
Reasons for dropouts: 6 did not continue
coming to the clinic byweek 2 for unknown
reasons, and 1 patient (in the venlafaxine
group) developed a manic episode and was
hospitalised
Selective reporting (reporting bias) High risk No numerical outcome data was reported
in the article, all data was presented in
graphs only.Do not have access to trial pro-
tocol
Other bias Low risk
Melvin 2006
Methods Duration: 12 weeks
Follow-up assessment points: Post-intervention, 6 months.
Funded by: Beyond Blue, Premiers Youth Suicide Taskforce, Department of Human
Services Victoria and Australian Rotary Health Research Fund
Participants N = 73
Adolescents only (12 to 18 years)
Depression diagnoses included: DSM-IV major depressive disorder (MDD), dysthymic
disorder (DD) and depressive disorder not otherwise specified (DDNOS)
Baseline risk of suicide: Participants who were ’actively suicidal’ were excluded from
the study, however ’suicidally depressed teenagers (who did not require hospitalisation)
were included. Measured using the Suicidal Ideation Questionnaire-Junior High School
Version (SIQ-JR; Reynolds 1987)
CBT = 26.05 (19.93)
Sertraline = 29.42 (27.24)
Sertraline + CBT = 30.64 (24.42)
Participants exhibiting active suicidality that required acute hospital admission were
excluded from the study
Baseline severity of depression:
CBT = 83.77 (13.8)
Sertraline = 84.92 (11.20)
Sertraline + CBT = 83.96 (15.01)
Comorbidity included: 69% were diagnosed with at least 1 comorbid disorder, 22%
were diagnosed with 2 or more
Comorbid disorder (n) CBT Sertraline Sertraline +
CBT
Anxiety disorders 8 9 10
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Dysthymic disorder 1 2 3
Conduct Disorder/ODD 2 3 1
Body dysmorphic disorder 1 0 0
Adjustment disorder with anxiety 0 1 0
Enuresis 1 0 0
Reading Disorder 0 1 0
Cannabis-related disorder NOS 0 1 0
Parent-child relational problem 5 6 8
Sibling relational problem 1 2 3
Age mean (SD): 15.3 (1.5)
CBT= 15.0
Sertraline = 15.5




CBT + Sertraline = 11:14
Setting: 3 clinics collocated with public child and adolescent mental health services
Excluded psychiatric diagnoses: Bipolar disorder, psychotic disorder, primary diagnosis
of substance abuse disorder, severe psychiatric disturbance that required acute hospital





Name: CBT course based in the Adolescent Coping with Depression Course (Clarke
1990). Modules included; goal setting, psycho education, affective education, self mon-
itoring, relaxation training, social skills training, pleasant events scheduling, cognitive
therapy and life goals planning
# sessions/length: Twelve 50 minute sessions over 12 weeks. Three ‘booster’ sessions
were also delivered over 3 months
Manualised (Y/N): Yes
Individual or group: Individual
Parent involvement: Parents who chose to participate received concurrent CBT sessions,
with 2 family sessions
Fidelity check: No formal check. Clinicians received weekly to twice weekly supervision
with an expert therapist. Peer supervision held weekly
Delivered by: 7 registered psychologists, a supervised probationary psychologist, 2 gen-
eral medical practitioners, and a social worker with experience in providing CBT for
adolescent depression. Training provided by chief investigators
Medication (Sertraline)
N = 26
Name (class & type): SSRI (Sertraline)
Dose (mg/day)/length: 25 mg/day for 1 week, increased to 50 mg/day at week 2 de-
pending on response and adverse events. Maximum dose of 100 mg/day administered
depending on clinical response and tolerability
Delivered how: Review sessions occurred every 2 to 3 weeks to monitor adverse effects,
and included education about depression but no CBT strategies
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Combination (Sertraline + CBT)
N = 25
Details as above (Y/N): Yes
Outcomes Clinician reported
The Schedule for Affective Disorders and Schizophrenia for School-Age Children-Life-
time Version (KSADS-PL; Kaufman 1997) was used to assess for disorder or remission,
which was based on DSM-IV criteria for full remission (i.e. 8 weeks asymptomatic)
The Global Assessment of Functioning Scale (GAF; APA 1994)
Dropouts:
Post-intervention:
CBT: 21/22 completed (1 dropout)
Sertraline: 21/26 completed treatment (5 dropouts)
Sertraline + CBT: 20/25 completed treatment (5 dropouts)
6 month follow-up:
CBT: 19/22 completed assessment (3 dropouts)
Sertraline: 23/26 completed assessment (3 dropouts)
Sertraline + CBT: 24/25 completed assessment (1 dropout)
Self reported
Reynolds Adolescent Depression Scale (RADS; Reynolds 1986)
The Suicidal Ideation Questionnaire-Junior High School Version (SIQ-JR; Reynolds
1987)
Parent reported
The Child Behaviour Checklist (CBCL; Achenbach 1991)
Additional Measures
The Global Assessment of Relational Functioning Scale (APA 1994)
Revised Children’s Manifest Anxiety Scale (RCMAS; Reynolds 1978)
The Self Efficacy Questionnaire for Depressed Adolescents (SEQ-DA; Tonge 2005)
Family Assessment Device General Functioning Scale (Epstein 1983)
Notes Dropouts during treatment to any or at least 1 adverse reaction: 6% discontinued medi-
cation due to adverse affects. These effects included slurred speech and dizziness, feeling
agitated and restless, and diarrhoea
Suicide-related outcome as an adverse event of treatment: 11.1% (n = 45) of participants
taking sertraline either alone or with CBT reported suicidal ideation. 1 participant in the
sertraline + CBT received an inpatient admission for several hours, however treatment
according to protocol was subsequently continued
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...subjects were randomly allocated by an
independent statistician using a computer
generated assignment to CBT, MED or
COMB”. pg. 1154
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Allocation concealment (selection bias) Low risk ”...allocated by an independent statistician.
..Allocation for those eligible for the trial
was concealed to all until after pre-treat-
ment assessment”. pg. 1154
Blinding (performance bias and detection
bias)
Assessors
High risk “Independent raters blind to treatment al-
location were not used because of resource
limitations but may have reduced the risk
of experimenter bias in assessments”. pg.
1160
Blinding (performance bias and detection
bias)
Participants
High risk Psychotherapy administered in
both groups and no placebo control used
for medication
Incomplete outcome data (attrition bias) Unclear risk ITT analysis: “data were analysed using
an intent-to-treat strategy to counter any
possible overestimation of treatment out-
comes, using the last observation carried
forward method (Nelson 1996)”. pg. 1155
Number randomised:
CBT: 22 Sertraline: 26 CBT +
Sertraline: 25 Total: 73
Number of dropouts during intervention
CBT: 1 Sertraline: 5 CBT +
Sertraline: 5 Total: 11
Number dropouts in follow-up:
CBT: 3 Sertraline: 3 CBT +
Sertraline: 1 Total:7
Number analysed post-intervention:
CBT: 22 Sertraline: 26 CBT +
Sertraline: 25 Total: 73
Number analysed follow-up 1:
CBT: 22 Sertraline: 26 CBT +
Sertraline: 25 Total: 73
Reasons for dropouts:
CBT: At post-intervention, 1 participant
reported symptoms had improved. At 6-
month follow-up, 2 refused to attend and
1 was unable to be located
Sertraline: At post-intervention, 2 partici-
pants reported symptoms had improved, 1
reported side effects, 1 dissatisfiedwith pro-
gramme and 1 did not pursue treatment. At
6-month follow-up, 1 participant refused
to attend, 1 was unable to be located and 1
’trial closure’
CBT + sertraline: At post-intervention:
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2 reported side effects, 1 symptoms im-
proved, 1 dissatisfied with programme, and
1 did not respond. At 6-month follow-up,
1 refused to attend
Selective reporting (reporting bias) Unclear risk Remission data not reported by group and
functioning data not reported in a useable
format. All other outcomes were reported.
Do not have access to trial protocol
Other bias Low risk
Riggs 2007
Methods Duration:16 weeks
Follow-up assessment points: Post-intervention
Funded by: National Institute on Drug Abuse, National Institutes of Health
Participants N = 126
Adolescent only (13 to 19 years)
Depression diagnoses included: DSM-IV current MDD episode
Baseline risk of suicide:Primary measure of suicidality was question 13 on the Childhood
Depression Rating Scale-Revised (CDRS-R; Poznanski 1996)
Baseline suicidality data: Fluoxetine + CBT = 25/63 (39.7%) CBT + placebo = 24/63
(38.1%). N = 13 displayed severe suicidal ideation (> 5 on CDRS-R Q13)
“Adolescents with past, current or intermittent suicidal ideation (39% at baseline) were
not excluded from study participation unless suicidal ideation were severe or they were
otherwise considered by the study physician and according to baseline CDRS-R ratings
(question 13) to be at high risk for a suicide attempt during the trial”
Baseline severity of depression: Children’s Depression Rating Scale-Revised (CDRS-R;
Poznanski 1996) mean t-score (SD):
Fluoxetine + CBT: 73.74 (8.51)
Placebo + CBT: 73.03 (7.70)
Comorbidity included: All participants had at least 1 non-tobacco Substance Use Dis-
order (SUD), and lifetime Conduct Disorder (CD)
Age mean (SD): Total = 17.16 (1.66)
Sex (M:F): Total = 85:41
Setting: Outpatient
Excluded psychiatric disorders: Current or past diagnosis of a psychotic disorder or of
bipolar disorder (type I or II)
Country: USA
Interventions Combination (Fluoxetine + CBT)
N = 63
Name: CBT approach using behavioural, cognitive behavioural and motivational en-
hancement techniques to help adolescents reduce their drug use. The programme con-
tains 1 session specifically on depression, helping adolescents to identify, manage and
regulate mood states that often trigger substance use
# sessions/length: 1 hour, 16 weekly sessions
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Manualised (Y/N): Yes
Individual or group: Individual
Parent involvement: Not specifically but could include up to 2 parent sessions
Fidelity check: Yes. All sessions videotaped and self rated by therapists. 32 videotapes
randomly selected and independently rated for adherence and fidelity. “...neither thera-
pist fell below present fidelity/adherence standards during any point of the study”
Delivered by: Study therapists (MD)whowere trained and certified by one of themanuals
developers. The developer provided ongoing supervision and quality monitoring
Name (class and type): SSRI (Fluoxetine)
Dose (mg/day)/length: 20 mg fixed daily dose
Delivered how: Monitoring of adverse effects and medication adherence was undertaken
by research nurses, and occurred either immediately before or after the weekly CBT
session
Combination (Placebo + CBT)
Details as above (Y/N): Yes
Outcomes Clinician reported
Remission of depression defined as as post-intervention Children’s Depression Rating
Scale-Revised (CDRS-R; Poznanski 1996) score of ≤ 28
Children’s Depression Rating Scale-Revised (CDRS-R; Poznanski 1996)
The Clinical Global Impression Improvement rating (CGI-I; Guy 1976)
Self reported
Question 13 on the Children’s Depression Rating Scale (CDRS-R; Poznanski 1996)
Additional Measures
Self reported number of non-tobacco drugs used in the past 30 days
Urine samples for substance use
Conduct Disorder: Number of self reported DSM-IV symptoms in the past 30 days
Notes Group means for age and gender not reported
Dropouts during treatment to any or at least 1 adverse reaction: Authors list 6 as ‘lost to
follow-up’ and 2 to ‘withdrew consent’ but do not disclose if this was due to an adverse
reaction
Suicide-related outcome as an adverse event of treatment: 5 participants (4 in the fluox-
etine + CBT group and 1 in the Placebo + CBT group were evaluated in an emergency
department or hospitalised for concerns of worsening suicidality during the study
Standard error and sample size was used to calculate standard deviations for group means
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “A non-blinded research pharmacist as-
signed eligible participants to receive 20
mg of fluoxetine hydrochloride or match-
ing placebo using a small block (6) ran-
domisation scheme of 20 blocks to achieve
balance in the treatment assignment”. pg.
1027
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Allocation concealment (selection bias) Low risk “Active medication and matching placebo
were prepared by the research pharmacy at
the University of Colorado at Denver and
Health Sciences Centre and then provided
to clinical research staff in pre-randomized
and pre-blinded medication bottles”. pg.
1027
Blinding (performance bias and detection
bias)
Assessors
Low risk “Research staff....remainedblinded tomed-
ication status throughout the trial”. pg.
1027
Blinding (performance bias and detection
bias)
Participants
Low risk : “.....participants remained blinded to
medication status throughout the trial”. pg.
1027
Incomplete outcome data (attrition bias) Low risk ITT analysis: “All analyses were intent-to-
treat (including all randomized study par-
ticipants)”. pg. 1028
Impulation method used: “Analyses of di-
chotomous and continuous primary out-
come measures over time used generalized
estimating equation (GEE) and likelihood
based methods, respectively. Both allow for
estimates of changes in repeated measures
in the presence of missing data, assuming
those data were missing at random”. pg.
1028
Number randomised:
Combination (Fluoxetine + CBT): 63
Combination (Placebo + CBT): 63 To-
tal: 126
Number of dropouts during intervention:
Combination (Fluox-
etine+CBT): 11 Combination (Placebo +
CBT):9 Total:20
Number analysed post-intervention:
Combination (Fluoxetine + CBT): 63
Combination (Placebo + CBT): 63 To-
tal:126
Reasons for dropouts: Fluoxetine + CBT: 4
participants went to jail/detention, 3 went
to residential treatment at facility and were
unable to continue the study, 3 were lost to
follow-up and 1 moved out of area
Placebo + CBT: 1 participant went to
jail/detention, 3 were lost to follow-up, 3
moved out of area and 2 withdrew consent
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Selective reporting (reporting bias) Unclear risk No group data on suicide outcomes re-
ported. All other outcomes specified in
methods reported. Do not have access to
trial protocol
Other bias Low risk
TADS 2004
Methods Duration: 12 weeks acute treatment, 6 weeks continuation treatment and 18 weeks
maintenance treatment
Follow-up assessment points: Post-intervention (12weeks), 18weeks (after continuation)
, 36 weeks (after maintenance)
Funded by: National Institution of Mental Health to Duke University Medical Centre
Participants N = 439
Adolescent only (12 to 17 years)
Depression diagnoses included:DSM-IVMajorDepressiveDisorder (MDD) and a score
of 45 or more on the CDRS-R (Poznanski 1996)
Baseline risk of suicide:
*data obtained from Table 2, 2004 paper





Fluoxetine + CBT: 27.33 (18.51)
Placebo: 24.20 (16.46)
Analysed according to a cut-off score of ≤ 31
CBT: 27/107 (25.2%)
Fluoxetine: 28/107 (26.2%)
Fluoxetine + CBT: 42/106 (39.6%)
Participants excluded if deemed ‘high risk’ because of a suicide attempt requiring medical
attention within 6 months. Also excluded on the basis of having a clear intent or active
plan to attempt suicide, or suicidal ideation accompanied by a disorganised family unable
to guarantee adequate safety monitoring
Baseline severity of depression:
*data obtained from Table 1, 2004 paper, t-scores presented
Children’s Depression Rating Score (CDRS-R; Poznanski 1996):
CBT: 75.37 (6.32)
Fluoxetine: 74.73 (6.74)
Fluoxetine + CBT: 75.67 (6.53)
Placebo: 76.14 (6.11)
Comorbidity included:
Comorbidity (%) CBT Fluoxetine Fluoxetine+CBT
Placebo
Any psychiatric comorbidity 58.18 43.12 55.66 51.
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35
Dysthymia 15.45 5.5 10.28
10.71
Anxiety 32.43 23.85 28.4
25.23
Disruptive behaviour 24.32 22.94 21.50 25.
00
Obsessive compulsive/tic 1.80 1.83 3.74 3.57
Substance use 0.90 2.75 2.80 0
Attention-deficit/hyperactivity 12.61 11.93 13.08 16.
96
Taking medications 3.60 2.75 3.74 8.93
Age mean (SD): Total = 14.6 (1.54)
CBT = 14.62 (1.50)
Fluoxetine = 14.50 (1.57)
CBT + Fluoxetine = 14.6 (1.48)




CBT + Fluoxetine = 47:60
Placebo = 53:59
Setting: Outpatient
Excluded psychiatric disorders: Current or past diagnosis of bipolar disorder, severe con-
duct disorder, current substance abuse or dependence, pervasive developmental disorder




Name: CBT modules included psycho education about depression and it’s causes, goal-
setting, mood monitoring, increasing pleasant activities, social problem-solving, and
cognitive restructuring
# sessions/length: Fifteen 1 hour sessions during stage 1, 6 additional sessions for partial
responders and bi-weekly sessions for full responders in stage 2, and 3 sessions (1 every
6 weeks) in stage 3
Manualised (Y/N): Yes
Individual or group: Individual
Parent involvement: 1 to 3 conjoint parent and adolescent sessions took place
Fidelity check: Not reported
Delivered by: Not reported
Medication (Fluoxetine)
N = 109
Name (class and type): Fluoxetine (SSRI)
Dose (mg/day)/length: 10 mg/day and increased up to 40 mg/day by week 8. At week
12, dose raised to 50 to 60mg/day for ‘partial responders’ and ‘full responders’ remained
on same fluoxetine dose
Delivered how: Monitoring and status and medication effects occurred during 20 to 30
minute visits. Clinician also offered general encouragement about the effectiveness of
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Schedule for Affective Disorder and Schizophrenia for School-Age Children-Present and
Lifetime Version (K-SADS-P-L; Kaufman 1997)
This was used to define remission i.e. those who had did not have a continuing or new
mood disorder since the last interview according to the K-SADS-PL).It was unclear if
DSM-IV or ICD time criteria were employed
Children’s Depression Rating Scale-Revised (CDRS-R; Poznanski 1996)
Self reported
Reynolds Adolescent Depression Scale (RADS; Reynolds 1986).
Suicidal ideation Questionnaire-Junior High School Version (SIQ-JR; Reynolds 1987)
Additional Measures
Clinical Global Impression Improvement (CGI-I; Guy 1976)
Child and Adolescent Impact Assessment (Angold 1998)
Columbia University classification scheme of the US Food and Drug Administration
analyses of antidepressant-associated suicidal events
Notes Dropouts during treatment to any or at least 1 adverse reaction:
Suicide-related outcome as an adverse event of treatment: 24 (5.5%) of participants




CBT + Fluoxetine: 5 (4.7)
Placebo: 3 (2.7)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Eligible participants were randomly as-
signed...using a computerized stratified
randomisation, a 1:1:1:1 treatment alloca-
tion ratio, permuted blocking (first block
size = 4, with subsequent random block
sizes of 4 and 8) within each striatum, and
site and sex stratification variables”. pg. 808
Allocation concealment (selection bias) Low risk “Participants were randomly assigned...at
the coordinating centre”. pg. 449
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Blinding (performance bias and detection
bias)
Assessors
Low risk “TADS used 2 primary measures of de-
pression status assessed...by an indepen-
dent evaluator blind to condition”. pg. 448
Blinding (performance bias and detection
bias)
Participants
High risk “Participants and all study staff remained
masked in the ‘pills only’ condition (flu-
oxetine therapy and placebo) until the end
of stage 1 (week 12). Patients and treat-
ment providers in the combination and
CBT conditions were aware of treatment
assignment”. pg. 1133
Incomplete outcome data (attrition bias) Unclear risk “The primary analyses of remission rates.
..were conducted using an “intention to
treat” (ITT) approach in which the analy-
sis included all participants randomized to
treatment regardless of protocol adherence
and/or treatment completion”. pg. Under
heading Data Analysis, 2009
Imputation method: LOCF
Number randomised:
CBT: 111 Fluoxetine: 109 Fluoxetine
+ CBT: 107 Placebo: 112 Total: 439
Number of dropouts during intervention
CBT: 41 Fluoxetine: 38 Fluoxetine
+ CBT: 23 Placebo: 14 Total: 116
Number of dropouts in follow-up (18
weeks):
CBT: 21 Fluoxetine: 37 Fluoxetine
+ CBT: 15 Placebo: 8 Total: 81
Number of dropouts in follow-up (36
weeks):
CBT: 25 Fluoxetine: 21 Fluoxe-
tine+CBT:23 Placebo: 15 Total: 84
Number analysed post-intervention:
CBT: 111 Fluoxetine: 109 Fluoxetine
+ CBT:107 Placebo: 112 Total: 439
Number analysed follow-up 1 (18 weeks):
CBT: 111 Fluoxetine: 109 Fluoxetine
+ CBT:107 Total: 327
Number analysed follow-up 2 (36 weeks):
CBT: 111 Fluoxetine: 109 Fluoxetine
+ CBT: 107 Total: 327
For active treatment arms: 84/327 exited
the study because of loss of follow-up or
withdrawal of consent (n = 21 for CBT +
fluoxetine, n = 32 for fluoxetine, n = 31 for
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CBT). 96/327 discontinued treatment be-
fore week 36 due to premature termination
or non-response at the end of stage 1 (n =
25 for CBT + fluoxetine, n = 39 for fluox-
etine, n = 32 for CBT), and this discontin-
uation was decided by the study physician
For placebo: 13/112 participants were ter-
minated prematurely from the study by
week 12 due to clinical worsening
Selective reporting (reporting bias) Unclear risk Trial protocol located
Other bias High risk Combination therapy group had an excess
of suicidal ideation at baseline relative to
fluoxetine or CBT
TASA 2009
Methods Duration: 6 months
Follow-up assessment points: Post-intervention (24 weeks)
Funded by: National Institute of Mental Health (NIMH)
Participants N = 124
Adolescent only (12 to 18 years)
Depression diagnoses included: DSM-IV Major Depressive Disorder (MDD), Dys-
thymic Disorder (DD) or Depressive Disorder not otherwise specified (DD-NOS). Par-
ticipants also had to obtain a score of 36 or more on the CDRS-R (Poznanski 1996)
Baseline risk of suicide: Participants were only eligible for participation if they had made
a suicide attempt in the last 90 days. Beck Scale for Suicidal Ideation (SSI; Beck et al
1979). Mean (SD):
Total = 6.3 (7.7)
CBT-SP = 5.0 (6.0)
SSRI = 3.9 (6.0)
SSRI+CBT-SP = 6.9 (8.2)
Baseline severity of depression: 96%met criteria forMDD and 10.5% hadDD andDD.
Children’s Depression Rating Scale-Revised (CDRS-R; Poznanski 1996). Mean (SD):
Total = 50.4 (12.6)
CBT-SP = 46.9 (14.7)
SSRI = 43.4 (11.1)
SSRI+CBT-SP= 52.1 (12.0)
Comorbidity included:
Comorbidity (%) CBT-SP SSRI SSRI+CBT-SP
Anxiety 23.5 28.6 63.4
ADHD 11.8 14.3 23.7
ODD/CD 0.0 35.7 15.1
Age mean (SD):
Total = 15.7 (1.5)
CBT-SP = 15.7 (1.5)
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SSRI = 15.6 (1.4)




SSRI + CBT-SP = 26:67
Setting: Academic sites
Excluded psychiatric diagnoses: Substance dependence, bipolar disorder, psychosis and




Name: CBT + Suicide prevention (CBT-SP). Modules included; chain analysis of the
suicide attempt, safety planning, formulation of the participants cognitive, behavioural,
affective and contextual problems, behavioural activation, cognitive restructuring, prob-
lem-solving, and relapse prevention
# sessions/length: Up to 22 sessions, length not specified
Manualised (Y/N): Yes
Individual or group: Individual
Parent involvement: Parent-youth sessions were included
Fidelity check: No formal check.Weekly telephone conferences were held to review cases
Delivered by: Trained psychotherapists under the supervision of senior experts
Medication (SSRI)
N = 14
Name (class and type): SSRI. Step 1: Monotherapy with an SSRI. Step 2: In the case of
non-response changed to a different SSRI. Stage 3: Medication changed to an alternative
class (venlafaxine, duloxetine, mirtazapine, or bupropion) with option of augmenting
with lithium or another SSRI
Dose (mg/day)/length: Not specified
Delivered how: By psychopharmacologists
Combination (SSRI + CBT-SP)
N = 93
Details as above (Y/N): Yes
Outcomes Clinician reported
Children’s Depression Rating Scale-Revised (CDRS-R; Poznanski 1996)
Children’s Global Assessment Scale (C-GAS; Shaffer 1983)
Self reported
Beck Depression Inventory (BDI; Beck 1988)
Beck Scale for Suicidal Ideation (SSI; Beck 1979a)
Recurrence of a suicidal event
Additional Measures
The Montgomery-Asberg Depression Rating Scale (MADRS; Montgomery 1979)
The Multidimensional Anxiety Scale for Children (MASC; March 1997)
The Clinical Global Impressions-Severity (CGI-S) and Improvement scales (CGI-I; Guy
1976)
58Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Notes Dropouts during treatment to any or at least 1 adverse reaction:
Suicide-related outcome as an adverse event of treatment: 19.5% of participants experi-
enced a suicide event and 12% made a suicide attempt. 1 participant died of suicide 20
days after completing the 24 week SSRI + CBT - SP treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “The study started as a randomized con-
trolled trial; however; after approximately 9
months of low enrolment despite intensive
recruitment efforts, the designwas changed
so that patients and their families could ac-
cept randomisation or choose which treat-
ment to receive”. pg. 998
Allocation concealment (selection bias) High risk As participants chose their treatment con-
dition, allocation concealment is not appli-
cable
Blinding (performance bias and detection
bias)
Assessors
Low risk “Independent evaluators were trained to
ensure interrater reliability and remained
blind to patient treatment assignment”. pg.
999
Blinding (performance bias and detection
bias)
Participants
High risk “Most (n = 104) chose their treatment
rather than being randomized”. pg. 1000
Incomplete outcome data (attrition bias) Unclear risk “The data were analysed with an intent-to-
treat approach”. pg. 999
Imputation method: LOCF
Number enrolled (included non-ran-
domised participants):
CBT-SI: 17 SSRI: 14 SSRI
+ CBT-SP: 93 Total: 124
Number of dropouts during intervention
CBT-SI: 6 SSRI: 6 SSRI
+ CBT-SP: 26 Total: 36
Number analysed post-intervention:
CBT-SI: 17 SSRI: 14 SSRI+
CBT-SP: 93 Total: 124
Reasons for dropout: 2 participants re-
ported suicidal intent with inability to
commit to safety plan, 5 showed lack of ad-
herence to treatment, 9 had a need for dif-
ferent treatments and services and 23 with-
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drew consent or failed to return for visits
for unspecified reasons
Selective reporting (reporting bias) High risk Only total and combination treatment out-
comes reported. Do not have access to trial
protocol
Other bias High risk The SSRI +CBT - SP group had higher lev-
els of depression severity at baseline com-
pared with the SSRI or CBT alone group.
The SSRI + CBT - SP group also had a
higher prevalence of comorbid anxiety and
more functional impairment than the other
2 groups
Only 20/124 participants were ran-
domised, the remaining 104/124 chose
their treatment option
ADHD: Attention Deficit Hyperactvity Disorder; b.i.d: twice daily; CDI: Children’s Depression Inventory; CDRS-R; Childrens De-
pression Rating Scale-Revised; DSM-III: Diagnostic and Statistical Manual of Mental Disorders, Third Edition; DSM-IV: Diag-
nostic and Statistical Manual of Mental Disorders, Fourth Edition; HMO: Health Maintenance Organisation; ICD: Internation
Classification of Diseases; ITT: Intention to Treat; NHS: National Health Service; NOS: Not Otherwise Specified; ODD; Oppo-
sitional Definant Disorder; q.i.d: four times daily; SD: Standard Deviation; SSRI: Selective Serotonin REuptake Inhibitor; TAU:
Treatment As Usual; t.i.d: three times daily.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Cheung 2008 Antidepressant versus placebo only, no psychological intervention
Dujovne 1994 Randomised cross-over trial, which is an exclusion criteria
Emslie 2002 (Eli 2002) Trial did not include a suitable comparison condition
Emslie 2004 Medical algorithm
Findling 2008 Trial did not include a suitable comparison condition
Fristad 2009 Trial did not include a suitable comparison condition.
King 2009 Trial did not include a suitable comparison condition
Tang 2009 Trial did not include a suitable comparison condition
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TORDIA 2008 Treatment of resistant depression
Wagner 2003 Antidepressant versus placebo only, no psychological intervention
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D A T A A N D A N A L Y S E S
Comparison 1. Psychological therapy versus antidepressant medication




participants Statistical method Effect size
1 Remission by clinical interview
(post-intervention) ITT
2 268 Odds Ratio (M-H, Random, 95% CI) 0.62 [0.28, 1.35]
2 Remission by clinical interview
(post-intervention) OC
2 220 Odds Ratio (M-H, Random, 95% CI) 0.52 [0.27, 0.98]
3 Remission by clinical interview
(six to nine months follow-up)
ITT
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
4 Remission by clinical interview
(six to nine months follow-up)
OC
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
5 Dropouts (post-intervention) 2 271 Odds Ratio (M-H, Random, 95% CI) 0.61 [0.11, 3.28]
6 Dropouts (six to nine months
follow-up)
2 223 Odds Ratio (M-H, Random, 95% CI) 1.17 [0.63, 2.19]
7 Suicidal ideation
(post-intervention)
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
8 Suicidal ideation (six to nine
months follow-up)
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
9 Suicidal ideation
(post-intervention)
2 268 Mean Difference (IV, Random, 95% CI) -3.12 [-5.91, -0.33]
10 Suicidal ideation (six to nine
months follow-up)
2 268 Mean Difference (IV, Random, 95% CI) -2.89 [-5.49, -0.28]
11 Suicidal ideation (12 months
follow-up)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
12 Remission by cut-off
(post-intervention)
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
13 Remission by cut-off (six to
nine months follow-up)
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
14 Remission by cut-off (12
months follow-up)




1 Mean Difference (IV, Random, 95% CI) Totals not selected
16 Depression symptoms clinician
rated (CDRS-R) (six to nine
months follow-up)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
17 Depression symptoms clinician
rated (CDRS-R) (12 months
follow-up)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
18 Depression symptoms self rated
(post-intervention)
2 255 Std. Mean Difference (IV, Random, 95% CI) 0.16 [-0.69, 1.01]
19 Depression symptoms self rated
(six to nine months follow-up)
2 268 Std. Mean Difference (IV, Random, 95% CI) -0.04 [-0.51, 0.42]
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20 Depression symptoms self rated
(12 months follow-up)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
21Functioning (post-intervention) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
22 Functioning (six to nine
months follow-up)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
Comparison 2. Combination therapy versus antidepressant medication




participants Statistical method Effect size
1 Remission by clinical interview
(post-intervention) ITT
3 419 Odds Ratio (M-H, Random, 95% CI) 1.50 [0.99, 2.27]
2 Remission by clinical interview
(post-intervention) OC
3 378 Odds Ratio (M-H, Random, 95% CI) 1.56 [0.98, 2.47]
3 Remission by clinical interview
(six to nine months follow-up)
ITT
2 203 Odds Ratio (M-H, Random, 95% CI) 1.93 [0.93, 4.00]
4 Remission by clinical interview
(six to nine months follow-up)
OC
2 193 Odds Ratio (M-H, Random, 95% CI) 1.94 [0.88, 4.27]
5 Remission by clinical interview
(12 months follow-up)
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
6 Dropouts (post-intervention) 4 627 Odds Ratio (M-H, Random, 95% CI) 0.89 [0.49, 1.63]
7 Dropouts (six to nine months
follow-up)
3 420 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.54, 1.64]
8 Dropouts (12 months follow-up) 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
9 Suicidal ideation
(post-intervention)
2 388 Odds Ratio (M-H, Random, 95% CI) 0.75 [0.26, 2.16]
10 Suicidal ideation (six to nine
months follow-up)
2 344 Odds Ratio (M-H, Random, 95% CI) 0.53 [0.06, 4.58]
11 Suicidal ideation (12 months
follow-up)
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
12 Suicidal ideation
(post-intervention)
2 267 Mean Difference (IV, Random, 95% CI) -2.57 [-5.53, 0.40]
13 Suicidal ideation (six to nine
months follow-up)
2 267 Mean Difference (IV, Random, 95% CI) -1.89 [-4.50, 0.72]
14 Suicidal ideation (12 months
follow-up)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
15 Remission by cut-off
(post-intervention)
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
16 Remission by cut-off (six to
nine months follow-up)
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
17 Remission by cut-off (12
months follow-up)




2 415 Mean Difference (IV, Random, 95% CI) -0.27 [-4.95, 4.41]
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19 Depression symptoms clinician
rated (CDRS-R) (six to nine
months follow-up)
2 408 Mean Difference (IV, Random, 95% CI) -0.27 [-2.26, 1.72]
20 Depression symptoms clinician
rated (CDRS-R) (12 months
follow-up)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
21 Depression symptoms self rated
(post-intervention)
4 618 Std. Mean Difference (IV, Random, 95% CI) -0.07 [-0.25, 0.12]
22 Depression symptoms self rated
(six to nine months follow-up)
4 610 Std. Mean Difference (IV, Random, 95% CI) -0.06 [-0.28, 0.17]
23 Depression symptoms self rated
(12 months follow-up)
2 368 Std. Mean Difference (IV, Random, 95% CI) -0.26 [-0.46, -0.05]
24 Functioning (post-intervention) 3 396 Std. Mean Difference (IV, Random, 95% CI) 0.09 [-0.11, 0.28]
25 Functioning (six to nine
months follow-up)
3 385 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.12, 0.28]
26 Functioning (12 months
follow-up)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
Comparison 3. Combination therapy versus psychological therapy




participants Statistical method Effect size
1 Remission by clinical interview
(post-intervention) ITT
2 265 Odds Ratio (M-H, Random, 95% CI) 1.61 [0.38, 6.90]
2 Remission by clinical interview
(post-intervention) OC
2 222 Odds Ratio (M-H, Random, 95% CI) 1.82 [0.38, 8.68]
3 Remission by clinical interview
(six to nine months follow-up)
ITT
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
4 Remission by clinical interview
(six to nine months follow-up)
OC
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
5 Dropouts (post-intervention) 2 265 Odds Ratio (M-H, Random, 95% CI) 1.23 [0.12, 12.71]
6 Dropouts (six to nine months
follow-up)
2 231 Odds Ratio (M-H, Random, 95% CI) 0.75 [0.40, 1.42]
7 Suicidal ideation
(post-intervention)
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
8 Suicidal ideation (six to nine
months follow-up)
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
9 Suicidal ideation
(post-intervention)
2 265 Mean Difference (IV, Random, 95% CI) 0.60 [-2.25, 3.45]
10 Suicidal ideation (six to nine
months follow-up)
2 265 Mean Difference (IV, Random, 95% CI) 1.78 [-2.29, 5.85]
11 Suicidal ideation (12 months
follow-up)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
12 Remission by cut-off
(post-intervention)
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
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13 Remission by cut-off (six to
nine months follow-up)
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
14 Remission by cut-off (12
months follow-up)




1 Mean Difference (IV, Random, 95% CI) Totals not selected
16 Depression symptoms clinician
rated (CDRS-R) (six to nine
months follow-up)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
17 Depression symptoms clinician
rated (CDRS-R) (12 months
follow-up)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
18 Depression symptoms self rated
(post-intervention)
2 265 Std. Mean Difference (IV, Random, 95% CI) -0.28 [-1.41, 0.84]
19 Depression symptoms self rated
(six to nine months follow-up)
2 265 Std. Mean Difference (IV, Random, 95% CI) -0.16 [-0.63, 0.31]
20 Depression symptoms self rated
(12 months follow-up)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
21Functioning (post-intervention) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
22 Functioning (six to nine
months follow-up)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
Comparison 4. Combination therapy versus psychological therapy plus placebo




participants Statistical method Effect size
1 Dropouts (post-intervention) 4 249 Odds Ratio (M-H, Random, 95% CI) 0.98 [0.42, 2.28]
2 Suicidal ideation
(post-intervention)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
3 Remission by cut-off
(post-intervention)
2 173 Odds Ratio (M-H, Random, 95% CI) 2.15 [1.15, 4.02]
4 Remission by cut-off (12 months
follow-up)




3 239 Std. Mean Difference (IV, Random, 95% CI) -0.52 [-0.78, -0.26]
6 Depression symptoms self rated
(post-intervention)
3 123 Std. Mean Difference (IV, Random, 95% CI) -0.34 [-0.70, 0.02]
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Analysis 1.1. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 1 Remission
by clinical interview (post-intervention) ITT.
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 1 Remission by clinical interview (post-intervention) ITT
Study or subgroup Psychological therapy
Antidepressant








Melvin 2006 5/22 5/26 25.0 % 1.24 [ 0.31, 4.98 ]
TADS 2004 53/111 71/109 75.0 % 0.49 [ 0.28, 0.84 ]
Total (95% CI) 133 135 100.0 % 0.62 [ 0.28, 1.35 ]
Total events: 58 (Psychological therapy), 76 (Antidepressant medication)
Heterogeneity: Tau2 = 0.14; Chi2 = 1.47, df = 1 (P = 0.22); I2 =32%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours antidepressant Favours psychological
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Analysis 1.2. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 2 Remission
by clinical interview (post-intervention) OC.
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 2 Remission by clinical interview (post-intervention) OC
Study or subgroup Psychological therapy
Antidepressant








Melvin 2006 5/21 5/21 19.5 % 1.00 [ 0.24, 4.14 ]
TADS 2004 53/87 71/91 80.5 % 0.44 [ 0.23, 0.85 ]
Total (95% CI) 108 112 100.0 % 0.52 [ 0.27, 0.98 ]
Total events: 58 (Psychological therapy), 76 (Antidepressant medication)
Heterogeneity: Tau2 = 0.02; Chi2 = 1.06, df = 1 (P = 0.30); I2 =6%
Test for overall effect: Z = 2.03 (P = 0.042)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours antidepressant Favours psychological
Analysis 1.3. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 3 Remission
by clinical interview (six to nine months follow-up) ITT.
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 3 Remission by clinical interview (six to nine months follow-up) ITT
Study or subgroup Psychological therapy
Antidepressant








Melvin 2006 10/22 13/26 0.83 [ 0.27, 2.60 ]
0.05 0.2 1 5 20
Favours antidepressant Favours psychological
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Analysis 1.4. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 4 Remission
by clinical interview (six to nine months follow-up) OC.
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 4 Remission by clinical interview (six to nine months follow-up) OC
Study or subgroup Psychological therapy
Antidepressant








Melvin 2006 10/18 13/20 0.67 [ 0.18, 2.49 ]
0.05 0.2 1 5 20
Favours antidepressant Favours psychological
Analysis 1.5. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 5 Dropouts
(post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 5 Dropouts (post-intervention)
Study or subgroup Psychological therapy
Antidepressant








Melvin 2006 1/25 5/26 32.2 % 0.18 [ 0.02, 1.62 ]
TADS 2004 41/111 38/109 67.8 % 1.09 [ 0.63, 1.90 ]
Total (95% CI) 136 135 100.0 % 0.61 [ 0.11, 3.28 ]
Total events: 42 (Psychological therapy), 43 (Antidepressant medication)
Heterogeneity: Tau2 = 1.01; Chi2 = 2.48, df = 1 (P = 0.12); I2 =60%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours psychological Favours antidepressant
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Analysis 1.6. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 6 Dropouts
(six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 6 Dropouts (six to nine months follow-up)
Study or subgroup Psychological therapy
Antidepressant








Melvin 2006 3/24 3/21 13.3 % 0.86 [ 0.15, 4.79 ]
TADS 2004 25/90 21/88 86.7 % 1.23 [ 0.63, 2.41 ]
Total (95% CI) 114 109 100.0 % 1.17 [ 0.63, 2.19 ]
Total events: 28 (Psychological therapy), 24 (Antidepressant medication)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours psychological Favours antidepressant
Analysis 1.7. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 7 Suicidal
ideation (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 7 Suicidal ideation (post-intervention)
Study or subgroup Psychological therapy
Antidepressant








TADS 2004 5/91 18/97 0.26 [ 0.09, 0.72 ]
0.02 0.1 1 10 50
Favours psychological Favours antidepressant
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Analysis 1.8. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 8 Suicidal
ideation (six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 8 Suicidal ideation (six to nine months follow-up)
Study or subgroup Psychological therapy
Antidepressant








TADS 2004 3/76 10/73 0.26 [ 0.07, 0.98 ]
0.02 0.1 1 10 50
Favours psychological Favours antidepressant
Analysis 1.9. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 9 Suicidal
ideation (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 9 Suicidal ideation (post-intervention)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Melvin 2006 22 19.41 (19.64) 26 24.23 (26.9) 4.5 % -4.82 [ -18.02, 8.38 ]
TADS 2004 111 11.4 (10.44) 109 14.44 (11.13) 95.5 % -3.04 [ -5.89, -0.19 ]
Total (95% CI) 133 135 100.0 % -3.12 [ -5.91, -0.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.19 (P = 0.028)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 10 Suicidal
ideation (six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 10 Suicidal ideation (six to nine months follow-up)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Melvin 2006 22 13.5 (9.09) 26 20.96 (26.12) 5.9 % -7.46 [ -18.19, 3.27 ]
TADS 2004 111 9.5 (9.1) 109 12.1 (11.1) 94.1 % -2.60 [ -5.28, 0.08 ]
Total (95% CI) 133 135 100.0 % -2.89 [ -5.49, -0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.74, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 11 Suicidal
ideation (12 months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 11 Suicidal ideation (12 months follow-up)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
TADS 2004 111 9 (8.7) 109 11.5 (10.8) -2.50 [ -5.09, 0.09 ]
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Analysis 1.12. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 12
Remission by cut-off (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 12 Remission by cut-off (post-intervention)
Study or subgroup Psychological therapy
Antidepressant








TADS 2004 18/111 25/109 0.65 [ 0.33, 1.28 ]
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Analysis 1.13. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 13
Remission by cut-off (six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 13 Remission by cut-off (six to nine months follow-up)
Study or subgroup Psychological therapy
Antidepressant








TADS 2004 71/111 59/109 1.50 [ 0.88, 2.58 ]
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Analysis 1.14. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 14
Remission by cut-off (12 months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 14 Remission by cut-off (12 months follow-up)
Study or subgroup Psychological therapy
Antidepressant








TADS 2004 69/111 72/109 0.84 [ 0.49, 1.47 ]
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Analysis 1.15. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 15
Depression symptoms clinician rated (CDRS-R) (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 15 Depression symptoms clinician rated (CDRS-R) (post-intervention)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
TADS 2004 111 42.06 (9.18) 109 36.3 (8.18) 5.76 [ 3.46, 8.06 ]
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Analysis 1.16. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 16
Depression symptoms clinician rated (CDRS-R) (six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 16 Depression symptoms clinician rated (CDRS-R) (six to nine months follow-up)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
TADS 2004 111 28.49 (8.77) 109 28.44 (7.53) 0.05 [ -2.11, 2.21 ]
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Analysis 1.17. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 17
Depression symptoms clinician rated (CDRS-R) (12 months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 17 Depression symptoms clinician rated (CDRS-R) (12 months follow-up)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
TADS 2004 111 29.9 (7.4) 109 29 (6.4) 0.90 [ -0.93, 2.73 ]
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Analysis 1.18. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 18
Depression symptoms self rated (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 18 Depression symptoms self rated (post-intervention)









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Melvin 2006 22 66 (15.93) 13 72.92 (26) 43.1 % -0.34 [ -1.03, 0.36 ]
TADS 2004 111 67.96 (14.18) 109 60.58 (13.07) 56.9 % 0.54 [ 0.27, 0.81 ]
Total (95% CI) 133 122 100.0 % 0.16 [ -0.69, 1.01 ]
Heterogeneity: Tau2 = 0.31; Chi2 = 5.34, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours psychological Favours antidepressant
Analysis 1.19. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 19
Depression symptoms self rated (six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 19 Depression symptoms self rated (six to nine months follow-up)









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Melvin 2006 22 60.05 (18.1) 26 67.08 (20.25) 36.2 % -0.36 [ -0.93, 0.21 ]
TADS 2004 111 56.2 (13.92) 109 54.37 (13.01) 63.8 % 0.14 [ -0.13, 0.40 ]
Total (95% CI) 133 135 100.0 % -0.04 [ -0.51, 0.42 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 2.35, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 0.18 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 20
Depression symptoms self rated (12 months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 20 Depression symptoms self rated (12 months follow-up)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
TADS 2004 111 56.2 (12.6) 109 55.7 (11.9) 0.50 [ -2.74, 3.74 ]
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Analysis 1.21. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 21
Functioning (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 21 Functioning (post-intervention)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Melvin 2006 21 68.52 (8.13) 21 66.33 (10.11) 2.19 [ -3.36, 7.74 ]
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Analysis 1.22. Comparison 1 Psychological therapy versus antidepressant medication, Outcome 22
Functioning (six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 1 Psychological therapy versus antidepressant medication
Outcome: 22 Functioning (six to nine months follow-up)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Melvin 2006 17 67.76 (9.17) 20 68.15 (10.29) -0.39 [ -6.66, 5.88 ]
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Analysis 2.1. Comparison 2 Combination therapy versus antidepressant medication, Outcome 1 Remission
by clinical interview (post-intervention) ITT.
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 1 Remission by clinical interview (post-intervention) ITT
Study or subgroup Combination
Antidepressant








Clarke 2005 44/77 32/75 41.3 % 1.79 [ 0.94, 3.41 ]
Melvin 2006 4/25 5/26 8.1 % 0.80 [ 0.19, 3.40 ]
TADS 2004 78/107 71/109 50.6 % 1.44 [ 0.81, 2.57 ]
Total (95% CI) 209 210 100.0 % 1.50 [ 0.99, 2.27 ]
Total events: 126 (Combination), 108 (Antidepressant medication)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.04, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.053)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Combination therapy versus antidepressant medication, Outcome 2 Remission
by clinical interview (post-intervention) OC.
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 2 Remission by clinical interview (post-intervention) OC
Study or subgroup Combination
Antidepressant








Clarke 2005 44/77 32/75 52.2 % 1.79 [ 0.94, 3.41 ]
Melvin 2006 4/22 5/21 9.9 % 0.71 [ 0.16, 3.12 ]
TADS 2004 78/92 71/91 37.9 % 1.57 [ 0.74, 3.34 ]
Total (95% CI) 191 187 100.0 % 1.56 [ 0.98, 2.47 ]
Total events: 126 (Combination), 108 (Antidepressant medication)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.26, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.062)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours antidepressant Favours combination
78Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.3. Comparison 2 Combination therapy versus antidepressant medication, Outcome 3 Remission
by clinical interview (six to nine months follow-up) ITT.
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 3 Remission by clinical interview (six to nine months follow-up) ITT
Study or subgroup Combination
Antidepressant








Clarke 2005 69/77 62/75 59.2 % 1.81 [ 0.70, 4.65 ]
Melvin 2006 17/25 13/26 40.8 % 2.13 [ 0.68, 6.64 ]
Total (95% CI) 102 101 100.0 % 1.93 [ 0.93, 4.00 ]
Total events: 86 (Combination), 75 (Antidepressant medication)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.076)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Combination therapy versus antidepressant medication, Outcome 4 Remission
by clinical interview (six to nine months follow-up) OC.
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 4 Remission by clinical interview (six to nine months follow-up) OC
Study or subgroup Combination
Antidepressant








Clarke 2005 69/77 62/75 69.4 % 1.81 [ 0.70, 4.65 ]
Melvin 2006 17/21 13/20 30.6 % 2.29 [ 0.55, 9.52 ]
Total (95% CI) 98 95 100.0 % 1.94 [ 0.88, 4.27 ]
Total events: 86 (Combination), 75 (Antidepressant medication)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.65 (P = 0.098)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Combination therapy versus antidepressant medication, Outcome 5 Remission
by clinical interview (12 months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 5 Remission by clinical interview (12 months follow-up)
Study or subgroup Combination
Antidepressant








Clarke 2005 69/77 71/75 0.49 [ 0.14, 1.69 ]
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Analysis 2.6. Comparison 2 Combination therapy versus antidepressant medication, Outcome 6 Dropouts
(post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 6 Dropouts (post-intervention)
Study or subgroup Combination
Antidepressant








ADAPT 2007 11/105 6/103 22.1 % 1.89 [ 0.67, 5.32 ]
Clarke 2005 10/77 10/75 24.9 % 0.97 [ 0.38, 2.49 ]
Melvin 2006 5/25 5/26 14.7 % 1.05 [ 0.26, 4.18 ]
TADS 2004 23/107 38/109 38.3 % 0.51 [ 0.28, 0.94 ]
Total (95% CI) 314 313 100.0 % 0.89 [ 0.49, 1.63 ]
Total events: 49 (Combination), 59 (Antidepressant medication)
Heterogeneity: Tau2 = 0.15; Chi2 = 5.06, df = 3 (P = 0.17); I2 =41%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Combination therapy versus antidepressant medication, Outcome 7 Dropouts
(six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 7 Dropouts (six to nine months follow-up)
Study or subgroup Combination
Antidepressant








ADAPT 2007 7/94 7/97 26.4 % 1.03 [ 0.35, 3.07 ]
Melvin 2006 1/24 3/21 5.7 % 0.26 [ 0.02, 2.72 ]
TADS 2004 23/96 21/88 67.9 % 1.01 [ 0.51, 1.98 ]
Total (95% CI) 214 206 100.0 % 0.94 [ 0.54, 1.64 ]
Total events: 31 (Combination), 31 (Antidepressant medication)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.22, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.82)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Combination therapy versus antidepressant medication, Outcome 8 Dropouts
(12 months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 8 Dropouts (12 months follow-up)
Study or subgroup Combination
Antidepressant








Clarke 2005 40/53 28/50 2.42 [ 1.05, 5.59 ]
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Analysis 2.9. Comparison 2 Combination therapy versus antidepressant medication, Outcome 9 Suicidal
ideation (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 9 Suicidal ideation (post-intervention)
Study or subgroup Combination
Antidepressant








ADAPT 2007 16/101 13/100 51.8 % 1.26 [ 0.57, 2.78 ]
TADS 2004 8/90 18/97 48.2 % 0.43 [ 0.18, 1.04 ]
Total (95% CI) 191 197 100.0 % 0.75 [ 0.26, 2.16 ]
Total events: 24 (Combination), 31 (Antidepressant medication)
Heterogeneity: Tau2 = 0.40; Chi2 = 3.17, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Combination therapy versus antidepressant medication, Outcome 10 Suicidal
ideation (six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 10 Suicidal ideation (six to nine months follow-up)
Study or subgroup Combination
Antidepressant








ADAPT 2007 13/98 9/94 54.3 % 1.44 [ 0.59, 3.56 ]
TADS 2004 2/79 10/73 45.7 % 0.16 [ 0.03, 0.77 ]
Total (95% CI) 177 167 100.0 % 0.53 [ 0.06, 4.58 ]
Total events: 15 (Combination), 19 (Antidepressant medication)
Heterogeneity: Tau2 = 2.00; Chi2 = 5.76, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 Combination therapy versus antidepressant medication, Outcome 11 Suicidal
ideation (12 months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 11 Suicidal ideation (12 months follow-up)
Study or subgroup Combination
Antidepressant








TADS 2004 2/79 10/73 0.16 [ 0.03, 0.77 ]
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Analysis 2.12. Comparison 2 Combination therapy versus antidepressant medication, Outcome 12 Suicidal
ideation (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 12 Suicidal ideation (post-intervention)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Melvin 2006 25 23.2 (20.24) 26 24.23 (26.9) 5.2 % -1.03 [ -14.06, 12.00 ]
TADS 2004 107 11.79 (11.69) 109 14.44 (11.13) 94.8 % -2.65 [ -5.69, 0.39 ]
Total (95% CI) 132 135 100.0 % -2.57 [ -5.53, 0.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.090)
Test for subgroup differences: Not applicable
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Analysis 2.13. Comparison 2 Combination therapy versus antidepressant medication, Outcome 13 Suicidal
ideation (six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 13 Suicidal ideation (six to nine months follow-up)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Melvin 2006 25 19.28 (17.72) 26 20.96 (26.12) 4.6 % -1.68 [ -13.89, 10.53 ]
TADS 2004 107 10.2 (8.8) 109 12.1 (11.1) 95.4 % -1.90 [ -4.57, 0.77 ]
Total (95% CI) 132 135 100.0 % -1.89 [ -4.50, 0.72 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 2.14. Comparison 2 Combination therapy versus antidepressant medication, Outcome 14 Suicidal
ideation (12 months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 14 Suicidal ideation (12 months follow-up)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
TADS 2004 107 9.9 (8.4) 109 11.5 (10.8) -1.60 [ -4.18, 0.98 ]
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Analysis 2.15. Comparison 2 Combination therapy versus antidepressant medication, Outcome 15
Remission by cut-off (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 15 Remission by cut-off (post-intervention)
Study or subgroup Combination
Antidepressant








TADS 2004 40/107 25/109 2.01 [ 1.11, 3.63 ]
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Analysis 2.16. Comparison 2 Combination therapy versus antidepressant medication, Outcome 16
Remission by cut-off (six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 16 Remission by cut-off (six to nine months follow-up)








TADS 2004 55/107 59/109 0.90 [ 0.53, 1.53 ]
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Analysis 2.17. Comparison 2 Combination therapy versus antidepressant medication, Outcome 17
Remission by cut-off (12 months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 17 Remission by cut-off (12 months follow-up)
Study or subgroup Combination
Antidepressant








Clarke 2005 40/53 28/50 43.9 % 2.42 [ 1.05, 5.59 ]
TADS 2004 70/107 72/109 56.1 % 0.97 [ 0.55, 1.71 ]
Total (95% CI) 160 159 100.0 % 1.45 [ 0.60, 3.52 ]
Total events: 110 (Combination), 100 (Antidepressant medication)
Heterogeneity: Tau2 = 0.28; Chi2 = 3.13, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 2.18. Comparison 2 Combination therapy versus antidepressant medication, Outcome 18
Depression symptoms clinician rated (CDRS-R) (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 18 Depression symptoms clinician rated (CDRS-R) (post-intervention)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
ADAPT 2007 100 42.5 (16.8) 99 40 (13.9) 42.6 % 2.50 [ -1.78, 6.78 ]
TADS 2004 107 33.65 (8.62) 109 35.98 (8.15) 57.4 % -2.33 [ -4.57, -0.09 ]
Total (95% CI) 207 208 100.0 % -0.27 [ -4.95, 4.41 ]
Heterogeneity: Tau2 = 8.63; Chi2 = 3.84, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
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Analysis 2.19. Comparison 2 Combination therapy versus antidepressant medication, Outcome 19
Depression symptoms clinician rated (CDRS-R) (six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 19 Depression symptoms clinician rated (CDRS-R) (six to nine months follow-up)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
ADAPT 2007 98 36.4 (15.3) 94 34.8 (13.4) 22.8 % 1.60 [ -2.46, 5.66 ]
TADS 2004 107 27.62 (8) 109 28.44 (7.53) 77.2 % -0.82 [ -2.89, 1.25 ]
Total (95% CI) 205 203 100.0 % -0.27 [ -2.26, 1.72 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 1.08, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 2.20. Comparison 2 Combination therapy versus antidepressant medication, Outcome 20
Depression symptoms clinician rated (CDRS-R) (12 months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 20 Depression symptoms clinician rated (CDRS-R) (12 months follow-up)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
TADS 2004 107 28.3 (6.8) 109 29 (6.4) -0.70 [ -2.46, 1.06 ]
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Analysis 2.21. Comparison 2 Combination therapy versus antidepressant medication, Outcome 21
Depression symptoms self rated (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 21 Depression symptoms self rated (post-intervention)









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
ADAPT 2007 100 22.7 (15.4) 99 21.6 (14.8) 31.2 % 0.07 [ -0.21, 0.35 ]
Clarke 2005 77 20.1 (11.6) 75 19.6 (10.2) 25.7 % 0.05 [ -0.27, 0.36 ]
Melvin 2006 25 71.64 (18.28) 26 72.92 (16.84) 10.4 % -0.07 [ -0.62, 0.48 ]
TADS 2004 107 56.95 (12.24) 109 60.58 (13.07) 32.7 % -0.29 [ -0.55, -0.02 ]
Total (95% CI) 309 309 100.0 % -0.07 [ -0.25, 0.12 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.00, df = 3 (P = 0.26); I2 =25%
Test for overall effect: Z = 0.70 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 2.22. Comparison 2 Combination therapy versus antidepressant medication, Outcome 22
Depression symptoms self rated (six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 22 Depression symptoms self rated (six to nine months follow-up)









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
ADAPT 2007 98 18.9 (15.5) 93 15.5 (15) 29.6 % 0.22 [ -0.06, 0.51 ]
Clarke 2005 77 13.7 (11.5) 75 15 (11.4) 26.4 % -0.11 [ -0.43, 0.21 ]
Melvin 2006 25 63.32 (17.88) 26 67.08 (20.25) 12.7 % -0.19 [ -0.74, 0.36 ]
TADS 2004 107 51.51 (13.38) 109 54.37 (13.01) 31.4 % -0.22 [ -0.48, 0.05 ]
Total (95% CI) 307 303 100.0 % -0.06 [ -0.28, 0.17 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 5.40, df = 3 (P = 0.14); I2 =44%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours combination Favours antidepressant
91Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.23. Comparison 2 Combination therapy versus antidepressant medication, Outcome 23
Depression symptoms self rated (12 months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 23 Depression symptoms self rated (12 months follow-up)









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Clarke 2005 77 11.5 (11) 75 14.9 (10.1) 41.1 % -0.32 [ -0.64, 0.00 ]
TADS 2004 107 53.1 (12.1) 109 55.7 (11.9) 58.9 % -0.22 [ -0.48, 0.05 ]
Total (95% CI) 184 184 100.0 % -0.26 [ -0.46, -0.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.47 (P = 0.013)
Test for subgroup differences: Not applicable
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Analysis 2.24. Comparison 2 Combination therapy versus antidepressant medication, Outcome 24
Functioning (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 24 Functioning (post-intervention)









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
ADAPT 2007 101 52.1 (14.3) 100 50.7 (12.1) 50.7 % 0.11 [ -0.17, 0.38 ]
Clarke 2005 77 60.4 (10.1) 75 59.5 (9.5) 38.4 % 0.09 [ -0.23, 0.41 ]
Melvin 2006 22 66.14 (12.5) 21 66.33 (10.11) 10.9 % -0.02 [ -0.61, 0.58 ]
Total (95% CI) 200 196 100.0 % 0.09 [ -0.11, 0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 2 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 2.25. Comparison 2 Combination therapy versus antidepressant medication, Outcome 25
Functioning (six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 25 Functioning (six to nine months follow-up)









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
ADAPT 2007 98 57.2 (16.4) 94 57.8 (14.5) 50.0 % -0.04 [ -0.32, 0.24 ]
Clarke 2005 77 68.8 (8.4) 75 66.6 (8.7) 39.3 % 0.26 [ -0.06, 0.58 ]
Melvin 2006 21 68.19 (14.19) 20 68.15 (10.29) 10.7 % 0.00 [ -0.61, 0.62 ]
Total (95% CI) 196 189 100.0 % 0.08 [ -0.12, 0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.90, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours antidepressant Favours combination
Analysis 2.26. Comparison 2 Combination therapy versus antidepressant medication, Outcome 26
Functioning (12 months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 2 Combination therapy versus antidepressant medication
Outcome: 26 Functioning (12 months follow-up)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Clarke 2005 77 71.4 (8.7) 75 68.4 (7.6) 3.00 [ 0.40, 5.60 ]
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Analysis 3.1. Comparison 3 Combination therapy versus psychological therapy, Outcome 1 Remission by
clinical interview (post-intervention) ITT.
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 1 Remission by clinical interview (post-intervention) ITT








Melvin 2006 4/25 5/22 39.7 % 0.65 [ 0.15, 2.79 ]
TADS 2004 78/107 53/111 60.3 % 2.94 [ 1.67, 5.18 ]
Total (95% CI) 132 133 100.0 % 1.61 [ 0.38, 6.90 ]
Total events: 82 (Combination), 58 (Psychological)
Heterogeneity: Tau2 = 0.83; Chi2 = 3.58, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Combination therapy versus psychological therapy, Outcome 2 Remission by
clinical interview (post-intervention) OC.
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 2 Remission by clinical interview (post-intervention) OC








Melvin 2006 4/22 5/21 41.6 % 0.71 [ 0.16, 3.12 ]
TADS 2004 78/92 53/87 58.4 % 3.57 [ 1.75, 7.30 ]
Total (95% CI) 114 108 100.0 % 1.82 [ 0.38, 8.68 ]
Total events: 82 (Combination), 58 (Psychological)
Heterogeneity: Tau2 = 0.95; Chi2 = 3.72, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Combination therapy versus psychological therapy, Outcome 3 Remission by
clinical interview (six to nine months follow-up) ITT.
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 3 Remission by clinical interview (six to nine months follow-up) ITT








Melvin 2006 17/25 10/22 2.55 [ 0.78, 8.36 ]
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Analysis 3.4. Comparison 3 Combination therapy versus psychological therapy, Outcome 4 Remission by
clinical interview (six to nine months follow-up) OC.
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 4 Remission by clinical interview (six to nine months follow-up) OC








Melvin 2006 17/21 10/18 3.40 [ 0.81, 14.24 ]
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Analysis 3.5. Comparison 3 Combination therapy versus psychological therapy, Outcome 5 Dropouts (post-
intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 5 Dropouts (post-intervention)








Melvin 2006 5/25 1/22 39.9 % 5.25 [ 0.56, 48.95 ]
TADS 2004 23/107 41/111 60.1 % 0.47 [ 0.26, 0.85 ]
Total (95% CI) 132 133 100.0 % 1.23 [ 0.12, 12.71 ]
Total events: 28 (Combination), 42 (Psychological)
Heterogeneity: Tau2 = 2.27; Chi2 = 4.27, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Combination therapy versus psychological therapy, Outcome 6 Dropouts (six to
nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 6 Dropouts (six to nine months follow-up)








Melvin 2006 1/24 3/21 7.3 % 0.26 [ 0.02, 2.72 ]
TADS 2004 23/96 25/90 92.7 % 0.82 [ 0.42, 1.58 ]
Total (95% CI) 120 111 100.0 % 0.75 [ 0.40, 1.42 ]
Total events: 24 (Combination), 28 (Psychological)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Combination therapy versus psychological therapy, Outcome 7 Suicidal
ideation (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 7 Suicidal ideation (post-intervention)








TADS 2004 8/90 5/91 1.68 [ 0.53, 5.34 ]
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Analysis 3.8. Comparison 3 Combination therapy versus psychological therapy, Outcome 8 Suicidal
ideation (six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 8 Suicidal ideation (six to nine months follow-up)








TADS 2004 2/79 3/76 0.63 [ 0.10, 3.89 ]
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Analysis 3.9. Comparison 3 Combination therapy versus psychological therapy, Outcome 9 Suicidal
ideation (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 9 Suicidal ideation (post-intervention)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Melvin 2006 25 23.2 (20.24) 22 19.41 (19.64) 6.2 % 3.79 [ -7.62, 15.20 ]
TADS 2004 107 11.79 (11.69) 111 11.4 (10.44) 93.8 % 0.39 [ -2.56, 3.34 ]
Total (95% CI) 132 133 100.0 % 0.60 [ -2.25, 3.45 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 3.10. Comparison 3 Combination therapy versus psychological therapy, Outcome 10 Suicidal
ideation (six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 10 Suicidal ideation (six to nine months follow-up)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Melvin 2006 25 19.28 (17.72) 22 13.5 (9.09) 21.2 % 5.78 [ -2.14, 13.70 ]
TADS 2004 107 10.2 (8.8) 111 9.5 (9.1) 78.8 % 0.70 [ -1.68, 3.08 ]
Total (95% CI) 132 133 100.0 % 1.78 [ -2.29, 5.85 ]
Heterogeneity: Tau2 = 4.01; Chi2 = 1.45, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 Combination therapy versus psychological therapy, Outcome 11 Suicidal
ideation (12 months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 11 Suicidal ideation (12 months follow-up)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
TADS 2004 107 9.9 (8.4) 111 9 (8.7) 0.90 [ -1.37, 3.17 ]
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Analysis 3.12. Comparison 3 Combination therapy versus psychological therapy, Outcome 12 Remission by
cut-off (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 12 Remission by cut-off (post-intervention)








TADS 2004 40/107 18/111 3.08 [ 1.63, 5.84 ]
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Analysis 3.13. Comparison 3 Combination therapy versus psychological therapy, Outcome 13 Remission by
cut-off (six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 13 Remission by cut-off (six to nine months follow-up)








TADS 2004 55/107 71/111 0.60 [ 0.35, 1.02 ]
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Analysis 3.14. Comparison 3 Combination therapy versus psychological therapy, Outcome 14 Remission by
cut-off (12 months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 14 Remission by cut-off (12 months follow-up)








TADS 2004 70/107 69/111 1.15 [ 0.66, 2.00 ]
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Analysis 3.15. Comparison 3 Combination therapy versus psychological therapy, Outcome 15 Depression
symptoms clinician rated (CDRS-R) (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 15 Depression symptoms clinician rated (CDRS-R) (post-intervention)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
TADS 2004 107 33.79 (8.24) 111 42.06 (9.18) -8.27 [ -10.58, -5.96 ]
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Analysis 3.16. Comparison 3 Combination therapy versus psychological therapy, Outcome 16 Depression
symptoms clinician rated (CDRS-R) (six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 16 Depression symptoms clinician rated (CDRS-R) (six to nine months follow-up)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
TADS 2004 107 27.62 (8) 111 28.49 (8.77) -0.87 [ -3.10, 1.36 ]
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Analysis 3.17. Comparison 3 Combination therapy versus psychological therapy, Outcome 17 Depression
symptoms clinician rated (CDRS-R) (12 months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 17 Depression symptoms clinician rated (CDRS-R) (12 months follow-up)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
TADS 2004 107 28.3 (6.8) 111 29.9 (7.4) -1.60 [ -3.49, 0.29 ]
-20 -10 0 10 20
Favours combination Favours psychological
103Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.18. Comparison 3 Combination therapy versus psychological therapy, Outcome 18 Depression
symptoms self rated (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 18 Depression symptoms self rated (post-intervention)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Melvin 2006 25 71.64 (18.28) 22 66 (15.93) 47.5 % 0.32 [ -0.25, 0.90 ]
TADS 2004 107 56.95 (12.24) 111 67.96 (14.18) 52.5 % -0.83 [ -1.10, -0.55 ]
Total (95% CI) 132 133 100.0 % -0.28 [ -1.41, 0.84 ]
Heterogeneity: Tau2 = 0.61; Chi2 = 12.39, df = 1 (P = 0.00043); I2 =92%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 3.19. Comparison 3 Combination therapy versus psychological therapy, Outcome 19 Depression
symptoms self rated (six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 19 Depression symptoms self rated (six to nine months follow-up)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Melvin 2006 25 63.32 (17.88) 22 60.5 (18.1) 36.4 % 0.15 [ -0.42, 0.73 ]
TADS 2004 107 51.51 (13.38) 111 56.2 (13.92) 63.6 % -0.34 [ -0.61, -0.07 ]
Total (95% CI) 132 133 100.0 % -0.16 [ -0.63, 0.31 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 2.36, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 3.20. Comparison 3 Combination therapy versus psychological therapy, Outcome 20 Depression
symptoms self rated (12 months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 20 Depression symptoms self rated (12 months follow-up)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
TADS 2004 107 53.1 (12.1) 111 56.2 (12.6) -3.10 [ -6.38, 0.18 ]
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Analysis 3.21. Comparison 3 Combination therapy versus psychological therapy, Outcome 21 Functioning
(post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 21 Functioning (post-intervention)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Melvin 2006 22 66.14 (12.5) 21 68.52 (8.13) -2.38 [ -8.65, 3.89 ]
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Analysis 3.22. Comparison 3 Combination therapy versus psychological therapy, Outcome 22 Functioning
(six to nine months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 3 Combination therapy versus psychological therapy
Outcome: 22 Functioning (six to nine months follow-up)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Melvin 2006 21 68.19 (14.19) 17 67.76 (9.17) 0.43 [ -7.04, 7.90 ]
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Analysis 4.1. Comparison 4 Combination therapy versus psychological therapy plus placebo, Outcome 1
Dropouts (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 4 Combination therapy versus psychological therapy plus placebo
Outcome: 1 Dropouts (post-intervention)








Bernstein 2000 7/31 9/32 38.3 % 0.75 [ 0.24, 2.33 ]
Cornelius 2009 0/24 3/26 7.4 % 0.14 [ 0.01, 2.80 ]
Deas 2000 2/5 0/5 6.1 % 7.86 [ 0.28, 217.11 ]
Riggs 2007 11/63 9/63 48.2 % 1.27 [ 0.49, 3.31 ]
Total (95% CI) 123 126 100.0 % 0.98 [ 0.42, 2.28 ]
Total events: 20 (Combination), 21 (Psych plus placebo)
Heterogeneity: Tau2 = 0.14; Chi2 = 3.65, df = 3 (P = 0.30); I2 =18%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours combination Favours psych+placebo
106Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.2. Comparison 4 Combination therapy versus psychological therapy plus placebo, Outcome 2
Suicidal ideation (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 4 Combination therapy versus psychological therapy plus placebo
Outcome: 2 Suicidal ideation (post-intervention)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Riggs 2007 63 0.94 (0.8) 63 1 (0.9) -0.06 [ -0.36, 0.24 ]
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Analysis 4.3. Comparison 4 Combination therapy versus psychological therapy plus placebo, Outcome 3
Remission by cut-off (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 4 Combination therapy versus psychological therapy plus placebo
Outcome: 3 Remission by cut-off (post-intervention)








Bernstein 2000 12/24 7/23 27.2 % 2.29 [ 0.69, 7.55 ]
Riggs 2007 44/63 33/63 72.8 % 2.11 [ 1.01, 4.37 ]
Total (95% CI) 87 86 100.0 % 2.15 [ 1.15, 4.02 ]
Total events: 56 (Combination), 40 (Psych plus placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Combination therapy versus psychological therapy plus placebo, Outcome 4
Remission by cut-off (12 months follow-up).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 4 Combination therapy versus psychological therapy plus placebo
Outcome: 4 Remission by cut-off (12 months follow-up)








Riggs 2007 5/29 4/27 1.20 [ 0.29, 5.02 ]
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Analysis 4.5. Comparison 4 Combination therapy versus psychological therapy plus placebo, Outcome 5
Depression symptoms clinician rated (CDRS-R) (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 4 Combination therapy versus psychological therapy plus placebo
Outcome: 5 Depression symptoms clinician rated (CDRS-R) (post-intervention)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bernstein 2000 31 34.6 (8.9) 32 45.7 (16.5) 25.1 % -0.82 [ -1.34, -0.31 ]
Cornelius 2009 24 4.45 (7.06) 26 8.31 (8.97) 21.1 % -0.47 [ -1.03, 0.09 ]
Riggs 2007 63 25.99 (11.6) 63 30.55 (11.5) 53.8 % -0.39 [ -0.75, -0.04 ]
Total (95% CI) 118 121 100.0 % -0.52 [ -0.78, -0.26 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.86, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 3.92 (P = 0.000090)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours combination Favours psych plus placeb
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Analysis 4.6. Comparison 4 Combination therapy versus psychological therapy plus placebo, Outcome 6
Depression symptoms self rated (post-intervention).
Review: Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents
Comparison: 4 Combination therapy versus psychological therapy plus placebo
Outcome: 6 Depression symptoms self rated (post-intervention)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bernstein 2000 31 6.4 (8.3) 32 9.8 (7.8) 51.2 % -0.42 [ -0.92, 0.08 ]
Cornelius 2009 24 6.79 (7.94) 26 10.46 (10.8) 40.7 % -0.38 [ -0.94, 0.18 ]
Deas 2000 5 12 (4.95) 5 10.4 (3.65) 8.1 % 0.33 [ -0.92, 1.59 ]
Total (95% CI) 60 63 100.0 % -0.34 [ -0.70, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.21, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.87 (P = 0.062)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours combination Favours psych+placebo
A P P E N D I C E S
Appendix 1. Additional search strategies
PsycINFO MEDLINE EMBASE
1. exp Major Depression/
2. ”Depression (Emotion)“/










1. exp Depressive Disorder/
2. Depression/
3. (depress$ or dysthymi$).tw.
4. or/1-3
5. exp Psychotherapy/
6. exp Antidepressive Agents/
7. exp Serotonin Uptake Inhibitors/
8. 6 or 7





2. (depress$ or dysthymi$).tw.
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43. exp Antidepressant Drugs/
44. (benactyzine$or clorgyline$or deanol$
or iproniazid$ or isocarboxazid$ or
lithium carbonate$ or moclobemide$ or
nialamide$ or phenelzine$ or pizotyline$
or rolipram$ or sertraline$ or tranyl-
cypromine$).tw
45. (5-hydroxytryptophan$or amoxapine$
or bupropion$ or citalopram$ or fluoxe-
tine$ or fluvoxamine$ or maprotiline$ or
mianserin$ or paroxetine$ or quipazine$ or
ritanserin$ or sulpiride$ or trazodone$ or
tryptophan$ or viloxazine$).tw
46. (amitriptyline$ or clomipramine$
or desipramine$ or dothiepin$ or dox-
epin$ or imipramine$ or iprindole$
or lofepramine$ or nortriptyline$ or
opipramol$ or protriptyline$ or trim-
ipramine$).tw
13. (juvenile$ or underage$ or teen$ or
youth$ or pubescen$ or adolescen$).tw
14. (young adult$ or young men or young
women or young people or young person$)
.tw




















33. 20 and 26
34. 20 and 32































42. exp Antidepressant Agent/
43. exp Monoamine Oxidase Inhibitor/
44. exp Noradrenalin Uptake Inhibitor/
45. exp Serotonin Uptake Inhibitor/
46. exp Tetracyclic Antidepressant Agent/
47. exp Tricyclic Antidepressant Agent/
48. or/42-47




53. (juvenile$ or underage$ or teen$ or
youth$ or pubescen$ or adolescen$).tw
54. (young adult$ or young men or young
women or young people or young person$)
.tw
55. (undergraduate$ or college student$ or
high-school student$).tw
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(Continued)
47. exp Tricyclic Antidepressant Drugs/
48. exp Monoamine Oxidase Inhibitors/
49. exp Adrenergic Blocking Drugs/
50. exp Serotonin Reuptake Inhibitors/ or
exp Serotonin Antagonists/
51. (serotonin adj (uptake or reuptake or
re-uptake)).tw.
52. ssri$.tw.
53. (amoxapine$ or citalopram$ or
clomipramine$ or fenfluramine$ or fluoxe-
tine$ or fluvoxamine$ or norfenfluramine$
or paroxetine$ or sertraline$ or trazodone$
or zimeldine$).tw
54. or/43-53
55. 4 and 42 and 54
56. (juvenile$ or underage$ or teen$ or
youth$ or pubescen$ or adolescen$).tw
57. (young adult$ or young men or young
women or young people or young person$)
.tw




61. 55 and 60
62. limit 55 to (180 school age or 200 ado-
lescence )








70. ((singl$ or doubl$ or trebl$ or tripl$)
adj5 (blind$ or dummy or mask$)).tw
71. placebo$.mp.
72. MetaAnalysis/
73. (meta-analy$ or metaanaly$ or meta
analy$).tw.
74. systematic review$.tw.
75. exp Treatment Effectiveness Evalua-
tion/
76. exp Mental Health Program Evalua-
tion/
77. or/65-76





60. 49 and 59
61. exp Controlled Study/
62. (controlled trial$ or controlled study or
controlled studies).tw
63. exp Clinical Trial/
64. (clinical trial$ or clinical study or clin-
ical studies).tw
65. random$.tw.
66. Single Blind Procedure/
67. Double Blind Procedure/
68. ((singl$ or doubl$ or trebl$ or tripl$)
adj (blind$ or mask$ or dummy)).tw
69. placebo$.mp.
70. or/61-69
71. 60 and 70
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
One additional objective was added to the review following the publication of the protocol. Given the concern that antidepressant
medication may increase suicide related behaviours in children and adolescents, we felt it was important to assess the degree of suicide
related behaviours related to antidepressant medication. Therefore a final objective was:
6. To determine whether there is an increased risk of suicide related outcomes in children and adolescents treated with antidepressant
medication alone, compared with psychological therapy alone, or a combination of treatments.
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